University of Louisville

ThinkIR: The University of Louisville's Institutional Repository

Electronic Theses and Dissertations

5-2012

Expression of adipocyte/macrophage fatty acid binding protein promotes tumor growth and metastasis.

Ashley Simone Triplett
University of Louisville

Follow this and additional works at: <https://ir.library.louisville.edu/etd>

Recommended Citation

Triplett, Ashley Simone, "Expression of adipocyte/macrophage fatty acid binding protein promotes tumor growth and metastasis." (2012). *Electronic Theses and Dissertations*. Paper 1457.
<https://doi.org/10.18297/etd/1457>

This Doctoral Dissertation is brought to you for free and open access by ThinkIR: The University of Louisville's Institutional Repository. It has been accepted for inclusion in Electronic Theses and Dissertations by an authorized administrator of ThinkIR: The University of Louisville's Institutional Repository. This title appears here courtesy of the author, who has retained all other copyrights. For more information, please contact thinkir@louisville.edu.

**EXPRESSION OF ADIPOCYTE/MACROPHAGE FATTY ACID BINDING
PROTEIN PROMOTES TUMOR GROWTH AND METASTASIS**

By

**Ashley Simone Triplett
B.S., Tennessee State University, 2007
M.S., University of Louisville, 2009**

**A Dissertation
Submitted to the Faculty of the
School of Medicine of the University of Louisville
in Partial Fulfillment of the Requirements
for the Degree of**

Doctor of Philosophy

**Department of Microbiology and Immunology
University of Louisville
Louisville, KY**

May 2012

EXPRESSION OF ADIPOCYTE/MACROPHAGE FATTY ACID BINDING
PROTEIN PROMOTES TUMOR GROWTH AND METASTASIS

By

Ashley Simone Triplett
B.S., Tennessee State University, 2007
M.S., University of Louisville, 2009

A Dissertation Approved on

April 26, 2012

by the following Dissertation Committee:

Jill Suttles, Dissertation Director

Richard Miller

Douglas Taylor

Robert Mitchell

DEDICATION

This dissertation is dedicated to my late mother

Georgetta Triplett,

and my grandmother,

Tommie Triplett.

ACKNOWLEDGEMENTS

I would first like to express my deepest gratitude to my advisor, Dr. Jill Suttles. I am honored to have had the privilege to work with you. I truly appreciate your support and patience. You have always been so encouraging, enthusiastic, and supportive in all situations, and have truly made my Ph.D. experience positive and enjoyable. I admire you not only as a scientist, but as a woman. Throughout this difficult time, you have done a terrific job at balancing work and home life. As I continue on my career path, I will try to live up to the example that you have set, and hope to inspire future scientists that way that you have inspired me.

I would also like to express my sincere gratitude to Dr. Robert Stout, who is a truly strong and happy spirit. Thank you so very much for helping me during the rough times of my graduate career. I have learned a great deal from you. You have definitely turned me into a “macrophage person”.

I’d also like to thank the current and past lab members. I would first like to thank Bing Li, who is a huge contributor to this work. Thank you for helping me get started in the lab and with this project. You taught me a wide variety of techniques that I will keep throughout my career. Kim Head and Lihua Zhang, thank you for always being thorough and keeping the lab in tip-top shape. Richard Hansen and Meena Vanchinathan for helping me with those huge

mouse experiments. Meena, I am very appreciative of your help during the 13-hour work days. And finally, I'd like to thank the girls: PeiPei Zhu, Courtney George, and Kelly Casey for our many science and non-science discussions. You guys really made the lab a happy place. I will truly miss you all!

Thank you so very much to my committee members, Dr. Douglas Taylor and Dr. Robert Mitchell for serving on my committee despite your overwhelmingly busy schedule. I am grateful for all your advice. I'd also like to thank Dr. Richard Miller for helping me get through the dissertation/defense.

Finally, I would like to thank all my friends and family for supporting me throughout this time. I'd like to give the biggest thank you to my mother for never giving up on me and believing in my ability.

ABSTRACT

EXPRESSION OF ADIPOCYTE/MACROPHAGE FATTY ACID BINDING PROTEIN PROMOTES TUMOR GROWTH AND METASTASIS

Ashley Triplett

April 26, 2012

It has been estimated that 30% of all cancer deaths in the U.S. are associated with obesity. It is well-established that obesity promotes low-grade chronic inflammation, however the mechanisms by which obesity-induced chronic inflammation may promote cancer development and progression are not well-defined. Fatty acid binding proteins (FABPs), which are intracellular lipid chaperones, regulate both metabolic and inflammatory pathways. Of the nine FABP family members, adipocyte/macrophage-FABP (A-FABP) has been found to be highly expressed in macrophages in both mice and humans and its expression is increased in response to a high-fat diet. In the present study we examined the influence of A-FABP expression on tumor growth and metastasis in mice under conditions of normal or high-fat feeding. Wild-type (WT) and A-FABP knockout (A-FABP KO) mice were placed on a normal or high-fat diet prior to the injection of Lewis Lung Carcinoma cells (LL/2). When fed a normal diet, LL/2 tumor metastasis was significantly reduced in A-FABP KO mice relative to WT mice, whereas tumor growth in A-FABP KO and WT mice was similar. However, a high fat diet resulted in a significant increase in both tumor growth and

metastasis in WT, but not A-FABP KO mice. Western blot and RT-PCR analysis demonstrated that tumor-infiltrating macrophages isolated from A-FABP KO mice on a normal or high-fat diet have reduced pro-inflammatory cytokine production, NF- κ B activation, and decreased expression of metastasis-promoting proteins, MMP-9 and MMP-12. Immunohistochemical analysis showed reduced expression of CD31 in tumors from A-FABP KO mice on either diet compared to tumors from WT mice. Taken together, our data suggest that A-FABP contributes to tumor growth and metastasis and implicate A-FABP as a link between fat consumption and cancer progression.

TABLE OF CONTENTS

	<u>PAGE</u>
DEDICATION	iii
ACKNOWLEDGEMENTS	iv
ABSTRACT	v
LIST OF FIGURES	vii
INTRODUCTION	1
General	1
Macrophage Function and Plasticity	5
The Role of Macrophages in Cancer.....	8
The Role of Macrophages in Obesity.....	11
and Metabolic Diseases	
Obesity and Cancer	13
Fatty Acid Binding Proteins	17
The Relationship Between PPARs and FABP.....	23
The Role of A-FABP in Obesity and Other Metabolic Disease	
Models	30
Hypothesis and Significance	32
MATERIALS AND METHODS	35
RESULTS	43
The Role of A-FABP in Tumor Growth and Metastasis	43
The tumor microenvironment enhances A-FABP expression in	
macrophages.....	42

A-FABP deficiency suppresses metastasis but not tumor growth.....	44
A-FABP deficiency reduces the production of pro-inflammatory and metastasis-promoting proteins.....	44
Use of a small molecule inhibitor of A-FABP also suppresses metastasis.....	45
The Role of A-FABP in Tumor Growth and Metastasis in Diet-Induced Obese Mice.....	51
A-FABP expression increases in response to high fat consumption.....	51
A-FABP deficiency confers protection against increased tumor growth and metastasis in lean and obese mice.....	52
Tumors from high fat fed WT mice show an increase in macrophage infiltration.....	53
A-FABP deficiency, despite a normal or high fat diet, decreases the production of pro-inflammatory cytokines and proteins involved in metastasis.....	53
DISCUSSION.....	70
REFERENCES.....	76
CURRICULUM VITAE.....	88

LIST OF FIGURES

<u>FIGURE</u>	<u>PAGE</u>
Table 1. Family of fatty acid binding proteins.....	22
Table 2. Formula of Normal Diet.....	36
Table 3. Formula of High Fat Diet.....	37
1. Obesity trends amongst adults in the United States.....	3
2. The role of macrophages in obesity-related diseases and cancer.....	4
3. A-FABP and PPAR γ ligands.....	26
4. A-FABP expression restricts 13-HODE to the cytoplasm.....	27
5. A-FABP promotes inflammation in wild-type macrophages.....	28
6. A-FABP deficiency promotes an anti-inflammatory response and cholesterol efflux.....	29
7. Increased A-FABP expression in macrophages in response to the tumor microenvironment.....	47
8. A-FABP deficiency suppresses tumor metastasis.....	48
9. A-FABP deficient TIMs show decreased production of pro-inflammatory and metastasis-promoting proteins.....	49
10. HTS01037, a small molecule inhibitor of A-FABP, reduces lung metastasis and MMP production, but has no effect on tumor growth.....	50
11. Weight of WT and A-FABP ^{-/-} mice fed a normal or high fat diet.....	56
12. A-FABP expression in lean versus diet-induce obese mice.....	57
13. A-FABP deficiency protects against tumor growth in mice fed a high	

fat diet.....	58
14. Lung metastasis in WT and A-FABP ^{-/-} mice fed a normal or high fat diet.....	59
15. TIM-induced invasion of LL/2 cells.....	60
16. Composition of immune cell infiltration in tumors from WT and A-FABP ^{-/-} mice on a normal or high fat diet.....	62
17. TIM from normal and high fat diet fed A-FABP deficient mice show decreased production of pro-inflammatory and metastasis-promoting proteins.....	64
18. Decreased protein expression of MMP-9 in TIM from A-FABP ^{-/-} mice.....	66
19. Immunohistochemical staining in WT and A-FABP ^{-/-} tumors.....	67
20. Lipid deposition in WT and A-FABP ^{-/-} tumors from normal and high fat diet fed mice.....	68
21. NF-κB activation in TIM taken from WT and A-FABP ^{-/-} mice fed a high fat diet.....	69

INTRODUCTION

General Background

Obesity is an increasing problem amongst children and adults in the United States (**Figure 1**) and it is estimated that 30% of all cancer deaths in the U.S. are associated with obesity. Obesity has been shown to increase the risk, incidence, and mortality of several types of cancers including those of the breast, prostate, colon, pancreas, kidney, liver, esophagus, endometrium, and many others [1, 2]. It is well established that obesity promotes systemic low-grade chronic inflammation, and chronic inflammation is also involved in the pathogenesis of 15-20% of human tumors. The main inflammatory component both within the tumor and the adipose tissue of obese humans are macrophages [3-5]. In an obese state, there is increased recruitment and accumulation of macrophages into the adipose tissue. In lean mice, 10-15% of cells in the adipose tissue express the macrophage marker F4/80, whereas 45-60% of cells are F4/80⁺ in the adipose tissue of obese mice [6, 7]. Adipose tissue macrophages exhibit a polarized pro-inflammatory phenotype with increased production of various inflammatory cytokines such as interleukin-6 (IL-6) and

tumor necrosis factor- α (TNF- α), leading to a chronic inflammatory state. This, in turn, promotes the onset and progression of many diseases that collectively make up metabolic syndrome, including atherosclerosis, diabetes, and insulin resistance. In cancer, macrophages secrete a variety of growth factors, chemokines, and cytokines that potentiate inflammation, tumor cell growth, proliferation-and survival, angiogenesis, as well as invasion and metastasis [8-12]. However, the mechanism(s) by which obesity-induced chronic inflammation promotes cancer development and progression is not well defined. Herein, we demonstrate that adipocyte-fatty acid binding protein (A-FABP), which is expressed in macrophages and can influence their inflammatory phenotype, serves as a link between obesity and cancer via impacting the functional phenotype of tumor-infiltrating macrophages (**Figure 2**).

Obesity Trends Among U.S. Adults
 (*BMI ≥ 30 , or ~ 30 lbs. overweight for 5' 4" person)

Source: Behavioral Risk Factor Surveillance System, CDC.

Figure 1. Statistical description of obesity trends among adults in the United States. The Center for Disease Control and Prevention (CDC) conducted a study where they followed obesity trends in U.S. adults over a 24-year period. In 1987, the U.S. was a relatively lean country with less than 14% of state populations considered to be obese. By 2009, however, majority of U.S. state populations had 25% or more adults that were obese. Adapted from Behavioral Risk Factor Surveillance System, CDC.

Figure 2. The role of macrophages in obesity-related diseases and cancer.

Macrophages have a well-documented role in both obesity and cancer. Through the secretion of various cytokines, growth factors, fatty acids, and chemokines, macrophages promote the progression and development of several obesity-related diseases, including atherosclerosis and type 2 diabetes, as well as cancer. However the link between obesity-induced chronic inflammation and cancer progression remains elusive. Here, FABP expression in macrophages may serve as a link between a high fat diet and the progression of cancer.

Macrophage Function and Plasticity

The mononuclear phagocyte system is a subpopulation of immune cells that are generated from hematopoietic stem cells located in the bone marrow. Monocytes are released into the blood circulation and seed various tissues throughout the body. During inflammation and steady state, although the latter is less efficient, monocytes differentiate into macrophages or dendritic cells [13, 14]. Macrophages are highly versatile, multi-functional cells that are involved in the inflammatory response as well as common “janitorial” roles where they clear the interstitial environment of waste material [14, 15]. Because of the many duties that macrophages are involved in, they are able to take on distinct phenotypes [16, 17]. The acquisition of a distinct phenotype and activation status is highly dependent upon stimulatory factors that are present in the tissue microenvironment [18]. Several factors have been shown to alter macrophage phenotype and function including arachidonates, complement proteins, cytokines, stress hormones, apoptotic cells, catecholamines, and even fatty acids [18-24]. Several studies have used a characterization approach whereby gene expression profiles following cytokine or microbial stimulation of macrophages are used to classify macrophage subsets. From this, two subsets with distinct phenotypes have been described: classically activated M1 macrophages and alternatively activated M2 macrophages.

Classically activated macrophages are effector cells that employ pro-inflammatory and phagocytic functions during anti-microbial and anti-tumoral

immune responses. Upon activation by tissue cytokines and chemokines, notably IFN- γ , TNF- α , and TLR ligands, infiltrating macrophages will induce the activity of a combination of transcription factors, including signal transducer and activator of transcription (STAT) molecules and NF-kappa B (NF- κ B) [25, 26]. These transcription factors, in turn, up-regulate genes involved in inflammation and pathogen clearance, such as reactive oxygen species and nitric oxide [27, 28]. Although the pro-inflammatory cytokines that are produced by classically activated macrophages are imperative for host defense, they can also cause considerable damage to the host. For example, reports have demonstrated that macrophage-derived IL-6, IL-23, and IL-1 are associated with the development and expansion of T_H17 cells, and the subsequent production of IL-17 has been shown to contribute to autoimmune disease, including rheumatoid arthritis and inflammatory bowel disease [29-33]. Nonetheless, classical activation of macrophages is vital for the protection of the host against viral and microbial pathogens, and even tumor development, as long as the response stays tightly controlled.

In contrast, alternatively activated macrophages display anti-inflammatory properties and are involved in resolution of the inflammatory response followed by wound healing. Alternative activation of macrophages is induced in the presence of IL-4 or IL-13, and produce anti-inflammatory cytokines including IL-10 and TGF- β , along with increased arginase [34, 35]. Promotion of wound healing and tissue repair is induced by the production of various proteases, growth factors, and angiogenic factors such as vascular endothelial growth factor

(VEGF), matrix metalloproteinases (MMPs), and epidermal growth factor (EGF) [36].

Macrophage activation, however, is much more complex and can not be linearly classified as classically or alternatively activated. Rather than discrete stable subpopulations, some scientists believe that macrophages represent a spectrum of phenotypes, and there are several documented studies demonstrating the flexibility in macrophage programming, with macrophages shifting from one functional phenotype to another in response to microenvironmental signals [37]. For example, upon clearance of bacteria, macrophages will begin to phagocytose apoptotic cells and down-regulate pro-inflammatory gene transcription in favor of a tissue reparative phenotype [38, 39]. This clearly demonstrates phenotypical adaptation rather than substituting subsets.

Macrophages are indeed crucial for tissue homeostasis and host defense, but they can also have pathologic roles. For example, macrophages are involved in intracellular lipid accumulation and foam cell formation, thus contributing to the development and progression of atherosclerosis [40]; macrophage-derived TNF and IL-23 mediates the pathology of Crohn's disease [41]; macrophages are key regulators in demyelinating disease of the central nervous system, such as experimental autoimmune encephalomyelitis (EAE) in mice and multiple sclerosis in humans [42]; and they are heavily involved in tumorigenesis [43]. Due to their plastic nature and their role in disease pathology, macrophages may make for effective therapeutic targets via the manipulation of their functional phenotype.

The Role of Macrophages in Cancer

The association between inflammation and cancer development and progression is well established [4, 44, 45]. It is now clear that virtually all tumors contain an array of immune cells at densities ranging from subtle inflammation to heavy infiltration [46]. Infiltrating immune cells were originally thought to be involved in the eradication of tumors, and although there is evidence demonstrating anti-tumor responses, many of these cells, particularly innate immune cells, display tumor-supporting phenotypes. One of the main inflammatory components within the microenvironment of primary and secondary tumors are macrophages [3]. High density of tumor-infiltrating macrophages (TIM) is associated with reduced patient survival in many different forms of cancer, including cancer of the breast, prostate, bladder, kidney, endometrium, esophagus, as well as follicular lymphoma, and squamous cell carcinoma [47-51]. This poor prognosis is primarily due to the ability of TIM to produce bioactive molecules including growth factors, cytokines, chemokines, and matrix-modifying enzymes that promote tumor cell proliferation and growth, survival, angiogenesis, activation of epithelial-mesenchymal transition, as well as invasion and metastasis [8-10, 12, 52].

During tumorigenesis, monocytes enter tumors through blood vessels. Monocyte and macrophage infiltration can be found in early-stage tumors that are beginning to vascularize and late-stage tumors that are invasive and metastatic [9, 11, 52]. The constant recruitment of monocytes into tumors can be attributed to tumor-derived chemoattractants, including colony-stimulating factor-

1 (CSF-1), monocyte chemotactic protein-1 (MCP-1), CCL2, CCL3, CCL4, CCL5, CCL8, and VEGF [53]. Studies have demonstrated that the expression level of these proteins positively correlates with TIM numbers [54]. To further confirm the important role of macrophages in cancer progression, early studies were conducted using mice with a homozygous CSF-1 null mutation to deplete macrophages in a mouse model of breast cancer [55, 56]. Depletion of macrophages resulted in reduced progression of pre-invasive lesions to malignant lesions, as well as reduced lung metastases.

Of the many pro-tumoral functions that macrophages exhibit, angiogenesis is the most crucial for tumor growth since tumors require the development of new blood vessels for expansion [3, 57]. Via the production of many essential factors such as IL-1, TNF- α , IL-8, COX-2, MMP-9, and VEGF, TIM are able to contribute significantly to angiogenesis [58-64]. Within tumors, TIM cluster in areas of hypoxia, which up-regulates the transcription factor hypoxia-inducible factor-2 α (HIF-2 α). HIF-2 α activation, in turn, induces the expression of VEGF [65]. VEGF expression is also able to up-regulate the production of CSF-1, and together, both factors serve as chemoattractants for additional macrophage recruitment [66]. Studies have further demonstrated that the production of IL-8, IL-1, and TNF- α promotes proliferation and migration of endothelial cells, along with matrix remodeling and blood vessel formation induced by MMP-9 and VEGF, respectively.

In addition to angiogenic roles, TIM are also critical mediators in tumor cell invasion and metastasis [67, 68]. During the metastatic process, TIM infiltrate the

basement membrane where they secrete various MMPs that are able to degrade the basement membrane. This allows for the creation of an egress, whereby tumor cells can invade into surrounding tissues [8]. Multiphoton intravital imaging of the breast microenvironment showed that TIM also directly promote tumor cell intravasation into the blood stream [69, 70]. Using this technology, which consisted of transgenic mice expressing fluorescently tagged cancer cells, endothelial cells, and macrophages, allowed for the visualization of interactions between these cell types at the site of intravasation. Wyckoff and colleagues found that TIM increased the motility of tumor cells, which was amplified when tumor cells were in close proximity with perivascular TIM [69]. In fact, tumor cells were found to invade blood vessels only where perivascular TIM were located. The use of *Csf1^{op/op}* PyMT mice, which have reduced macrophage infiltration and a decrease in circulating cancer cells, demonstrated the functional importance of this interaction for intravasation. Moreover, a macrophage EGF-CSF paracrine loop was found to be crucial for intravasation, as inhibition of this signaling pathway led to reduced numbers of cancer cells in the blood stream [69]. Additional studies demonstrated that TIM also regulate the density of collagen fibers, which serve as tram lines for tumor cells and macrophages to travel along within the tumor stroma. Many of these fibers are bound to blood vessels, resulting in the accumulation of tumor cells at the vessels [71].

The Role of Macrophages in Obesity and Metabolic Diseases

In addition to having very important roles in the development and progression of cancer, macrophages are also heavily involved in obesity-related inflammation and metabolic syndrome [5, 72]. In 2003, two studies illustrated that in an obese state, macrophages infiltrate the adipose tissue and are primarily responsible for the inflammatory environment [6, 7]. Expanding adipocytes and neighboring pre-adipocytes produce signals that induce the recruitment and accumulation of macrophages into the adipose tissue in both mice and humans. During late-stage obesity, adipocyte death serves as an additional mechanism by which macrophages infiltrate the adipose tissue [73]. In addition to differences in the adipocyte to macrophage ratio, adipose tissue macrophages also display functional differences between lean and obese mice [74]. Adipose tissue macrophages in lean mice exhibit an anti-inflammatory, alternatively activated-like phenotype. These macrophages have increased production of IL-10, which plays a role in maintaining insulin sensitivity [74, 75]. In contrast, adipose tissue macrophages from obese mice have a pro-inflammatory, classically activated-like phenotype and they are typically found in 'crown-like' structures around dying adipocytes [72, 74]. There are several published studies supporting the idea that these macrophages are the primary cell type contributing to the pathogenesis of obesity-induced diseases, including insulin resistance, type 2 diabetes, and atherosclerosis [22, 76-78]. First, there is protection from obesity-induced inflammation and insulin resistance in mice lacking CC-chemokine receptor 2 (CCR2), which is a receptor that is required for the recruitment of inflammatory

monocytes and macrophages into tissues [79]. CCR2 and its ligand CCL2 are postulated to have a dominant role in the trafficking of monocytes and macrophages to the adipose tissue [79, 80]. Second, CD11c-DTR mice, which are used to selectively deplete CD11c⁺ classically activated macrophages, also show reduced inflammation in the adipose tissue along with improved insulin sensitivity [81]. Third, by genetically deleting IKK β in myeloid cells, Arkan and colleagues were able to reduce myeloid cell-mediated inflammation in the adipose tissue [82]. Additionally, reconstituting mice with JNK-deficient bone marrow conferred similar results [83]. Lastly, ablation of a G protein-coupled receptor GPR120, which mediates the anti-inflammatory actions of omega-3 unsaturated fatty acids, exacerbates inflammation in the adipose tissue and insulin resistance [84].

It has been suggested that saturated, but not unsaturated, fatty acids prompt the activation of M1-like macrophages in the adipose tissue of obese mice. This phenomenon is mediated by ligation of TLR-4 and subsequent signaling pathways [85-87]. For example, the infusion of lipids adequately induces adipose tissue inflammation and insulin resistance in wild-type but not TLR-4-deficient mice [88]. Moreover, studies have shown that high fat diet-induced insulin resistance requires TLR-4 expression by hematopoietic cells in the adipose tissue and liver [89, 90]. In addition to TLR-4 studies, others have shown that MyD88 signaling may link inflammation and metabolism. Deletion of MyD88 in mice confers more severe metabolic disease in response to a high fat

diet when compared to wild-type mice, suggesting that MyD88 may have a protective role [87].

Another macrophage-expressing factor that links metabolism and inflammation is adipocyte/macrophage fatty acid binding protein (A-FABP). Ongoing studies in our lab and others have demonstrated the influence of this protein on macrophage inflammatory function under conditions of metabolic stress.

Obesity and Cancer

Clinical and epidemiological studies have linked obesity and obesity-associated diseases to increased cancer risk, incidence, and mortality. Overweight and obesity led to an almost 2-fold increase in cancer risk in both men and women with a body mass index (BMI) of $>25 \text{ kg/m}^2$ [91]. This increase does, however, comply with the type of cancer. For example, in men with a BMI of $35\text{--}40 \text{ kg/m}^2$, there is about a 5-fold increase in hepatocellular carcinoma, 2-3 fold increase in oesophageal cancer [92], and even the slightest increase in BMI can put individuals at risk for cancers of the pancreas, kidney, gastrointestinal tract, and liver [93]. In fact, several studies focusing on kidney cancer reported a dose-response correlation between increasing weight or BMI and kidney cancer incidence [94-96]. Obesity and breast cancer incidence have consistently mirrored one another, with a 30-50% increase in breast cancer rates amongst obese women, and mortality and survival studies have shown that very obese

women, with a BMI of ≥ 40 kg/m² have a 3-fold increase in breast cancer death rates compared to lean women (BMI < 20.5 kg/m²) [97]. Cancer of the endometrium was the first to be recognized as being associated with obesity. Studies show a linear increase in endometrial cancer risk and increasing BMI [98, 99]. In regards to prostate cancer, evidence shows that although there is only a slightly higher risk of prostate cancer in obese men compared to lean men, prostate tumors in obese men are significantly more aggressive and there is a higher chance of recurrence after radical prostatectomy [100, 101]. In contrast, studies have shown that maintaining healthier weights can actually lower the risk for many cancers including colon, breast, endometrium, kidney, and oesophageal cancer [99]. In 2009, it was reported that 15-20% of cancer deaths was associated with obesity, however in 2010, the American Association for Cancer Research annual report showed that 30% of all cancer deaths in the United States were associated with obesity. Thus, this relationship is becoming an increasing problem, however the mechanism(s) behind the obesity and cancer association is poorly understood.

Currently, the strongest evidence to mechanistically link obesity to cancer are hormonal effects. For example, increased estrogen production in the adipose tissue of obese women is associated with increased breast cancer risk. This is partly due to increased expression and activity of aromatase, an enzyme that is responsible for the biosynthesis of estrogen, in both the adipose tissue and mammary gland [102]. Additionally, it is well established that obesity leads to the development of insulin resistance and chronic hyperinsulinaemia. Higher levels

of circulating insulin leads to a reduction of insulin-like growth factor binding protein 1 (IGFBP1), which in turn, increases the availability of insulin-like growth factor 1 (IGF1). Insulin and IGF1 both signal through insulin receptors to promote cellular proliferation and inhibit apoptosis in many cell types, thus contributing to tumorigenesis. Elevated levels in circulating insulin has also been identified as a risk factor for many cancers and is associated with late-stage disease and poor prognosis [103].

Excess adiposity is also associated with an increase in free fatty acids in the environment, and numerous studies have looked at fatty acid metabolism as a potential mechanism to link obesity to cancer. For example, under obese conditions, polyunsaturated fatty acids are chemically oxidized to generate high amounts of reactive oxygen species (ROS). ROS, in turn, promote cancer development via DNA damage. ROS generated from lipids can also lead to cyclooxygenase-2 (COX2) up-regulation, which in turn, promotes colorectal, breast, and prostate carcinogenesis [104, 105]. Hyperglycemia and elevated triglycerides, which are hallmarks of obesity, can also induce the generation of ROS and lead to tumorigenesis [104]. Fatty acid synthase (FAS), which is an enzyme that catalyzes fatty acid synthesis, is also associated with poor prognosis in breast and prostate cancer patients.

Park and colleagues showed that obesity is indeed a tumor promoter via the administration of a liver chemical carcinogen, diethylnitrosamine (DEN). DEN failed to induce hepatocellular carcinoma (HCC) on its own, however HCC did develop only in genetic or diet-induced obese mice, and the effect was just as

strong as the more common liver tumor promoter, phenobarbital [2]. Moreover, they found that the tumor-promoting effects of obesity in HCC were due to the low-grade chronic inflammatory state that it promotes, including elevated levels of TNF and IL-6 [2, 106]. It is well established that obesity promotes systemic low-grade chronic inflammation, but the influence of obesity-induced chronic inflammation in cancer development and progression hasn't been well explored. Adipose tissue is an organ of many functions that secretes a variety of pro-inflammatory adipokines and cytokines, including adiponectin, leptin, IL-6, MCP-1, IL-8, VEGF, and TNF- α , all of which have been implicated in metabolic diseases and cancer. Visceral adipose tissue, which has been described as being more metabolically active, correlates with circulating levels of leptin, which promotes proliferation, angiogenesis, and MMP expression in oesophageal and colon cancer [1]. Additionally, TNF-mediated activation of NF- κ B has been shown to increase nitric oxide (NO) production. NO serves as a substrate for the generation of ROS, and ROS in combination with other inflammatory cytokines, leads to insulin resistance and glucose intolerance. It has been proposed that insulin resistance, ROS, and inflammatory cytokines lead to a vicious cycle since these factors facilitate continuous NF- κ B activation, and this may be a potential hallmark in obesity-induced chronic inflammation and cancer [107]. Because macrophages are huge contributors to the inflammatory milieu in both adipose tissue and tumors, we decided to focus our work on this cell type in the context of obesity and cancer.

Fatty Acid Binding Proteins

Fatty acids are well known for their role in maintenance of cell structure and energy metabolism, but they also function as metabolic signaling molecules, thus regulating vital cellular and physiological processes. Fatty acids are capable of modulating the activity of G protein-coupled receptors (GPCRs) by serving as ligands for several GPCRs, including GPR40, GPR43, GPR84, and GPR120. In macrophages, GPR120 binds omega 3 fatty acids resulting in anti-inflammation and insulin sensitization [108]. Fatty acids can also activate and inhibit kinases, such as I kappa kinase β (IKK β), and serve as ligands for transcription factors, including peroxisome proliferator-activated receptors (PPARs) [109]. In order to carry out these tasks, fatty acid binding proteins (FABPs) are required for the trafficking and targeting of intracellular fatty acids and other bioactive lipids throughout the cell [110].

FABPs constitute a family of small (14-15 kDa), highly homologous intracellular lipid chaperones that coordinate lipid trafficking to various cellular compartments including lipid droplets for storage; the mitochondria for oxidation; the nucleus for regulation of gene transcription; and outside of the cell for autocrine and paracrine signaling. Most importantly, FABPs are strongly linked to the regulation of both metabolic and inflammatory pathways [110, 111]. Thus far, nine FABPs have been identified and include adipocyte (A-), heart (H-), intestinal (I-), brain (B-), epidermal (E-), ileal (Il-), testis (T-), and myelin (M-) FABPs.

However, the nomenclature can be misleading since no FABP is exclusive for a given tissue or cell type. In fact, there are tissues and cells that express more than one type of FABP. Extensive work has been conducted to elucidate the structure and ligand binding characteristics of FABPs. The structural characteristics of FABPs consist of β -barrels arranged in such a way that it forms an interior water-filled cavity where the ligand binds. All FABPs reversibly bind hydrophobic long chain fatty acids, with the specificity and affinity of ligand binding varying amongst the isoforms due to small structural differences. In general, FABPs bind saturated long-chain fatty acids with the highest affinity, followed by unsaturated fatty acids, and then polyunsaturated fatty acids, as well as eicosanoids [112-114]. Tissue distribution of FABP expression varies, ranging from fairly widespread, as is the case for H-FABP which has been shown to be expressed in a variety of tissues, to narrow, as is the case for A-FABP [110]. Generally, FABPs are abundantly expressed in tissues that are actively involved in lipid metabolism [115]. For example, FABPs make up 1-5% of all soluble cytosolic proteins in adipocytes, hepatocytes, and cardiac myocytes, which all undergo high rates of lipolysis. **Table 1** summarizes the type and locations of FABPs that have been discovered to date.

Our work focuses on adipocyte/macrophage fatty acid binding protein (A-FABP) (Gene: *FABP4*), also known as aP2 [116, 117]. It is best-characterized member in the FABP family. Initially, A-FABP expression had been thought to be restricted to adipocytes, where it is associated with adipocyte differentiation. However we, and others, have previously demonstrated that A-FABP is also

expressed in macrophages and our lab has shown strong expression of A-FABP in dendritic cells. A-FABP expression in macrophages becomes evident upon differentiation from monocytes, as well as by treatment with phorbol 12-myristate 13-acetate, lipopolysaccharide (LPS), peroxisome proliferator-activated receptor γ (PPAR- γ) agonists, insulin, oxidized low-density lipoprotein (ox-LDL), and tissue injury [118-121]. In contrast, atorvastatin, a cholesterol-lowering statin, reduces A-FABP expression in macrophages *in vitro* [122]. Treatment of macrophages with unsaturated fatty acids also results in A-FABP suppression in macrophages. Coleman et al., conducted a study wherein RAW 264.7 macrophages were pre-treated with various unsaturated fatty acids followed by stimulation with LPS, and despite being stimulated by a highly inflammatory factor, these macrophages maintained lower levels of A-FABP when compared to control-treated macrophages [123].

Macrophage A-FABP binds arachidonic acids and metabolites of the cyclooxygenase (COX) and lipoxygenase (LOX) pathways, including compounds that act as ligands for PPARs [124]. In fact, several A-FABP ligands have a high affinity for PPARs. PPARs are nuclear receptors consisting of three primary subtypes, α , β , and γ . PPARs regulate vital cellular processes that impact lipid homeostasis, inflammation, reproduction, adipogenesis, wound healing, and tumorigenesis. Previous studies from our lab have shown that in macrophages, A-FABP prevents cholesterol efflux via the inhibition of the PPAR- γ – liver X receptor- α (LXR- α) – ATP-binding cassette A1 (ABCA1) pathway, and thus contributes to macrophage foam cell formation in the context of atherosclerosis

[109, 125]. When A-FABP is present, it limits the availability of PPAR- γ ligands, thus preventing PPAR- γ activation and subsequent up-regulation of the genes involved in cholesterol efflux, LXR- α and ABCA1 (**Figure 5**). Conversely, in A-FABP^{-/-} macrophages, fatty acids are free to bind to PPAR- γ , resulting in LXR- α and ABCA1 expression, and the shuttling of cholesterol out of the cell (**Figure 6**) [109]. In parallel, A-FABP regulates the inflammatory response in macrophages (**Figures 5 and 6**). In A-FABP deficient macrophages, elevated PPAR- γ activity allows for suppression of NF- κ B activity, a mechanism which may be via ligand-dependent transrepression of NF- κ B, although this has yet to be proven. Here, PPAR- γ undergoes sumoylation in the ligand-binding domain upon activation, which targets PPAR- γ to nuclear co-repressor (NCoR)/histone deacetylase-3 (HDAC) complexes on inflammatory gene promoters. Because of this, the ubiquitylation/19S proteasome machinery, which indirectly mediates removal of co-repressor complexes required for gene transcription, is not recruited. Thus, NCoR complexes remain bound to promoters, and inflammatory genes are maintained in a repressed state [126]. Additionally, some fatty acids can also directly inhibit IKK activity. A-FABP^{-/-} macrophages also display impaired adaptor protein 1 (AP1) activity via inhibition of the JNK pathway [110, 127]. Relative to wild-type macrophages, A-FABP deficient macrophages show reduced expression of several pro-inflammatory mediators in response to LPS and CD40 ligand stimulation, including prostaglandin E₂, iNOS, IL-1 α , IL-1 β , IL-6, IL-12, MCP-1/CCL2, and TNF α . However in the presence of A-FABP, restriction of fatty acid nuclear localization allows for components of the NF- κ B pathway to be

activated, which is also a contributing factor to foam cell formation and inflammation in atherosclerosis as well as in a model of EAE [109, 126, 128].

Table 1. Family of fatty acid binding proteins.

Gene	Name	Alternate Names	Tissue/Cell Expression
<i>Fabp1</i>	Liver FABP	L-FABP	Liver, intestine, pancreas, kidney, lung, stomach
<i>Fabp2</i>	Intestinal FABP	I-FABP	Intestine, liver
<i>Fabp3</i>	Heart FABP	H-FABP, MDGI	Heart, skeletal muscle, brain, kidney, lung, stomach, testis, aorta, adrenal gland, mammary gland, placenta, ovary, brown adipose tissue
<i>Fabp4</i>	Adipocyte FABP	A-FABP, aP2	Adipocyte, macrophage, dendritic cell
<i>Fabp5</i>	Epidermal FABP	E-FABP, PA-FABP, mal1	Skin, tongue, adipocyte, macrophage, dendritic cell, mammary gland, brain, intestine, kidney, liver, lung, heart, skeletal muscle, testis, retina, lens, spleen
<i>Fabp6</i>	Ileal FABP	IL-FABP, I-BABP, gastrotropin	Ileum, ovary, adrenal gland, stomach
<i>Fabp7</i>	Brain FABP	B-FABP, MRG	Brain, glia cell, retina, mammary gland
<i>Fabp8</i>	Myelin FABP	M-FABP, PMP2	Peripheral nervous system, Schwann cell
<i>Fabp9</i>	Testis FABP	T-FABP	Testis, salivary gland, mammary gland

The Relationship Between PPARs and FABP

A-FABP and PPAR- γ share several ligands indicating a functional link between the two proteins (**Figure 3**). Two possible scenarios are 1) FABPs target ligands to PPARs, resulting in PPAR activation, or 2) FABPs sequester PPAR ligands, resulting in decreased ligand availability and PPAR inactivation. In 2001, Wolfrum and colleagues sought to understand how signaling molecules reached nuclear receptors such as PPARs. Using laser-scanning microscopy, they first showed that liver-FABP (L-FABP) and PPAR- α colocalized in the nucleus of mouse hepatocytes. Pull-down assays and immunoprecipitation proved that L-FABP and PPAR- α interacted directly, and further transactivation assays showed that PPAR α and γ transactivation correlated with intracellular L-FABP concentrations, suggesting that L-FABP transported PPAR ligands to the nucleus [129, 130]. Using CV-1 cells transfected with A-FABP, Helledie and colleagues demonstrated that A-FABP, when expressed at high levels, resulted in negative regulation of PPAR activation and PPAR-mediated gene transcription [131]. Our lab previously conducted a study where wild-type and A-FABP^{-/-} macrophage cell lines were treated with 13-HODE, a high affinity ligand that binds both A-FABP and PPAR γ (**Figure 4**). Using confocal microscopy, we were able to show that in wild-type macrophages, nuclear localization of 13-HODE was inhibited, whereas 13-HODE was free to enter the nucleus and bind to PPAR γ in the absence of A-FABP, suggesting that in macrophages, FABPs bind and sequester PPAR ligands, acting as negative regulators of PPAR activity. We have also demonstrated that in the absence of FABPs, PPAR activity is

enhanced [109], resulting in the up-regulation of LXR α and ABCA1 expression, which leads to enhanced cholesterol efflux and protection from atherosclerosis. The finding that A-FABP deficiency protects against atherosclerosis in the apoE-deficient murine model complements our data showing that FABPs act to sequester PPAR ligands.

In addition to a model of atherosclerosis, we have also shown that elevated PPAR activity due to A-FABP deficiency protects mice from developing EAE [128]. In this report, A-FABP deficient mice had lower levels of pro-inflammatory cytokine expression, including impaired IFN and IL-12 production, in the central nervous system tissue compared to wild-type mice, resulting in decreased disease incidence and clinical symptoms [128]. This evidence is also supported by findings demonstrating that PPAR agonists exert a protective effect against EAE development [132]. Moreover, FABPs have high affinity for retinoid-binding receptors, including retinoid X receptor (RXR), which is a heterodimeric partner of PPARs [133]. Retinoic acid influences macrophage inflammatory phenotype by down-regulating IL-12 production via NF- κ B inhibition [134]. Because A-FABP binds to retinoic acid, it may function as a negative regulator of RXRs as well. To complement this, we have shown that A-FABP deficient macrophages display elevated responses to agonists of RXR, and further published studies have shown that when combined with PPAR agonists, RXR agonists confer additional protection from EAE [135]. Thus, our data fit very well with literature supporting an anti-inflammatory role of PPARs in metabolic

and inflammatory diseases along with the functional link between FABPs and nuclear receptors.

Figure 3. A-FABP and PPAR γ ligands. Both A-FABP and PPAR γ share several ligands, thus creating a functional link between these two proteins.

Figure 4. A-FABP expression restricts 13-HODE, a PPAR γ ligand, to the cytoplasm. A, 13-HODE (10 μ M) (green) was restricted in the cytoplasm of macrophages in the presence of A-FABP, but able to enter the nucleus in A-FABP^{-/-} macrophages (turquoise). B, Quantitation of co-localization of 13-HODE in nucleus (** $p < 0.001$).

A-FABP^{+/+}
Macrophage

Figure 5. A-FABP promotes inflammation in wild-type macrophages. A-FABP expression in macrophages limits the availability of PPAR γ ligands, and in doing so, inhibits PPAR γ activity while allowing components of the NF- κ B pathway to be activated.

A-FABP^{-/-} Macrophage

Figure 6. A-FABP deficiency promotes an anti-inflammatory response and cholesterol efflux. In the absence of A-FABP, fatty acids are free to enter the nucleus, bind to and activate PPAR γ . This results in up-regulation of genes involved in cholesterol trafficking, including LXR α , ABCA1, and CD36. Enhanced PPAR γ activity also inhibits activation of the NF- κ B pathway via ligand-dependent transrepression. Additionally, some fatty acids can directly inhibit IKK activity.

The Role of A-FABP in Obesity and Other Disease Models

Despite the extensive work done on the structure and ligand binding properties of FABPs, there are still many questions regarding the primary functional role of these proteins. The elucidation of A-FABP function was facilitated by the production of A-FABP deficient animals generated by Dr. Gokhan Hotaslimigil at Harvard University School of Public Health. Mice deficient in A-FABP are healthy with no defects in metabolism or reproduction and development, however the effects of A-FABP deletion can be observed when mice are subjected to systemic stress such as diet-induced obesity or disease. When subjected to genetic or diet-induced obesity, A-FABP deficient mice, despite weighing slightly more than wild-type controls, are protected from development of insulin resistance and diabetes [124, 136, 137]. Hotamisligil and colleagues showed that free fatty acids from a high-fat diet induce the expression of TNF- α , a molecule which has been highly connected to obesity-related insulin resistance. This study further showed that by binding and shuttling free fatty acids to specific intracellular compartments, A-FABP regulates the expression of TNF- α . In the A-FABP deficient model, mice failed to express adipose tissue TNF- α and showed improved insulin resistance and glucose metabolism compared to wild-type mice [136, 137].

Numerous observations, including the documented role of PPAR γ in foam cell formation and the ability of PPAR γ to up-regulate A-FABP expression, spurred an examination of the influence of A-FABP deficiency in the development

and progression of atherosclerosis. In these studies, A-FABP deficient mice were cross-bred with the apoE-deficient background such that the apoE-deficient model of atherosclerosis could be exploited. The apoE^{-/-}, A-FABP^{-/-} mice displayed significant protection from the development of atherosclerosis when compared to apoE^{-/-}, A-FABP^{+/+} animals. Moreover, apoE^{-/-}, A-FABP^{-/-} mice fed a normal diet developed 88% less atherosclerosis while apoE^{-/-}, A-FABP^{-/-} mice fed a high fat, Western diet developed 91% less atherosclerosis when compared to apoE^{-/-}, A-FABP^{+/+} mice fed either diet, suggesting that A-FABP provides an increased protective effect under conditions of metabolic excess. Further bone marrow transplantation studies where A-FABP^{-/-}, ApoE^{-/-} bone marrow was transplanted into A-FABP^{+/+}, ApoE^{-/-} revealed that the atheroprotective effect of A-FABP deficiency was primarily due to its expression in macrophages [138].

The fact that mice under normal physiologic conditions do not have a compromised phenotype when A-FABP is deleted, but they benefit when faced with systemic inflammatory or metabolic stress, gives rise to the question of why A-FABP exists if it seems to promote dysfunction. Acutely activated signaling systems, such as in acute inflammation, display regulatory mechanisms to amplify and/or attenuate a particular response. A-FABP seems to be required to induce a strong inflammatory response. However too strong of a response can be damaging. In an obese state, macrophages are constantly exposed to excess free fatty acids and pro-inflammatory cytokines released from adipocytes. This may result in an increased and continuous expression of A-FABP in macrophages, leading to a sustained polarized pro-inflammatory phenotype and

systemic low-grade chronic inflammation. This scenario has been demonstrated in the promotion and progression of atherosclerosis, but could this also be the case in cancer?

Hypothesis and Significance

Published studies have suggested a link between FABP expression and cancer progression, but the focus has been on FABP expression in cancer cells themselves as opposed to primary cells of the host, and the results are quite mixed. For example, reduced levels of L-FABP, I-FABP, and A-FABP are associated with the progression of liver, colon, and bladder cancers [139-141], whereas increased levels of B-FABP and E-FABP have been found in the advancement of astrocytoma tumors and prostate cancer, respectively [142, 143]. Neiman and colleagues demonstrated that A-FABP expression in adipocytes promoted ovarian cancer cell metastasis to the omentum, an organ primarily composed of adipocytes, while A-FABP deficiency led to a significant reduction in metastatic tumor growth in mice [144]. However, many tumors display heavy immune cell infiltration, and the role of FABP expression in leukocytes in the regulation of tumor growth and progression has not been explored.

Furthermore, A-FABP expression levels in macrophages is up-regulated in response to a high fat diet, particularly saturated fatty acids found in a Western

diet, and contribute to a polarized pro-inflammatory phenotype in macrophages as well as the development and progression of a cluster of diseases that make up metabolic syndrome. One study conducted by Hancke et al., focused on A-FABP expression in the serum of breast cancer patients, and the results showed higher A-FABP levels in breast cancer patients compared to healthy patients, and this expression was increased even further in obese breast cancer patients [145]. Additionally, the A-FABP expression was found to be associated with increased breast cancer risk and positively correlated with tumor size and lymph node involvement [145], suggesting that A-FABP not only has a putative role in cancer progression, but may also exacerbate this disease under obese conditions.

Over the past few years, studies in our lab have focused on macrophage plasticity and how this can be used in the treatment of a variety of diseases. Our work has provided evidence that macrophages possess a spectrum of activation states rather than existing as distinct subsets. In response to changes in the microenvironment, macrophages can reversibly shift their phenotype through a multitude of patterns. For example, by treating macrophages with different cytokines, distinct functional phenotypes can be observed, and sequentially treating macrophages with multiple cytokines results in a succession through several functional phenotypes [18]. This can also be seen *in vivo* whereby distinct macrophage phenotypes that are established in aged or tumor-bearing mice can be altered by inducing changes in the microenvironment [24, 37]. As mentioned previously, A-FABP mediates both metabolic and inflammatory

pathways, thus regulating the outcome of innate and adaptive immune responses and making A-FABP a potential therapeutic target for several inflammatory and metabolic diseases, as well as cancer [110]. Moreover, it has been reported that a genetic polymorphism in the A-FABP locus in humans [146], which results in reduced A-FABP expression, produces a similar phenotype as in mice, suggesting that the biological roles of A-FABP are similar between species and inhibiting this protein in humans is feasible. The identification of small molecule inhibitors of A-FABP suggests that targeting this protein for therapeutic purposes is attainable, however this also requires a more in-depth understanding of how A-FABP functions on both a cellular and whole animal level. Herein, we address a more complete understanding of how A-FABP regulates cancer progression. Given our previous findings regarding the role of A-FABP in macrophage inflammatory function, we hypothesize that macrophage expression of A-FABP may influence the functional outcome of tumor-macrophage interactions in the tumor microenvironment. Moreover, because a high fat diet induces A-FABP expression in macrophages, we also hypothesize that A-FABP may serve as a link between high fat consumption and cancer progression.

MATERIALS AND METHODS

Mice and macrophage cell lines.

A-FABP^{-/-} mice were generated as previously described [137, 147], and back-crossed >10 generations onto a C57BL/6J background. A-FABP^{-/-} mice are bred and maintained at the University of Louisville Research Resources Facility. All animal care and experimental procedures used in this study were approved by the University of Louisville's Institutional Animal Care and Use Committee. A-FABP^{-/-} macrophage cell lines used in this study were generated by J2 retroviral transformation of bone marrow progenitors as previously described (CITATION).

Normal and High Fat Diet

High fat diet (60% kcal from fat) food and its matched low fat diet control (10% kcal from fat) was purchased from Research Diets, Inc. After being weaned, WT and A-FABP^{-/-} mice were placed on either diet for 120 days. Tumor studies were then performed. The formula of both the normal and high fat diet is below.

Table 2. Formula of Normal Diet

Formula Normal (10%) Diet

Product #	D12450B	
	gm%	kcal%
Protein	19.2	20
Carbohydrate	67.3	70
Fat	4.3	10
Total		100
kcal/gm	3.85	
Ingredient	gm	kcal
Casein, 80 Mesh	200	800
L-Cystine	3	12
Corn Starch	315	1260
Maltodextrin 10	35	140
Sucrose	350	1400
Cellulose, BW200	50	0
Soybean Oil	25	225
Lard*	20	180
Mineral Mix S10026	10	0
DiCalcium Phosphate	13	0
Calcium Carbonate	5.5	0
Potassium Citrate, 1 H ₂ O	16.5	0
Vitamin Mix V10001	10	40
Choline Bitartrate	2	0
FD&C Yellow Dye #5	0.05	0
Total	1055.05	4057

Formulated by E. A. Ulman, Ph.D., Research Diets, Inc., 8/26/98
and 3/11/99.

*Typical analysis of cholesterol in lard = 0.95 mg/gram.

Cholesterol (mg)/4057 kcal = 19

Cholesterol (mg)/kg = 18

Table 3. Formula of High Fat Diet

Formula High Fat (60%) Diet

Product #	D12492	
	gm%	kcal%
Protein	26.2	20
Carbohydrate	26.3	20
Fat	34.9	60
Total		100
kcal/gm	5.24	

Ingredient	gm	kcal
Casein, 80 Mesh	200	800
L-Cystine	3	12
Corn Starch	0	0
Maltodextrin 10	125	500
Sucrose	68.8	275.2
Cellulose, BW200	50	0
Soybean Oil	25	225
Lard*	245	2205
Mineral Mix, S10026	10	0
DiCalcium Phosphate	13	0
Calcium Carbonate	5.5	0
Potassium Citrate, 1 H ₂ O	16.5	0
Vitamin Mix, V10001	10	40
Choline Bitartrate	2	0
FD&C Blue Dye #1	0.05	0
Total	773.85	4057

Formulated by E. A. Ulman, Ph.D., Research Diets, Inc., 8/26/98
and 3/11/99.

*Typical analysis of cholesterol in lard = 0.95 mg/gram.

Cholesterol (mg)/4057 kcal = 232.8

Cholesterol (mg)/kg = 300.8

Tumor models.

LL/2 Lewis Lung Carcinoma cells were obtained from the late Dr. Gordon Ross of the James Graham Brown Cancer Center in Louisville, KY. Tumors were maintained by *in vivo* passage with limited intermittent culture *in vitro*. Tumor cells were injected subcutaneously into the left flank of wild-type C57BL/6J (Jackson Laboratories), A-FABP^{+/-}, or A-FABP^{-/-} mice. Five to seven mice were used in each group (10% WT, 10% A-FABP^{+/-}, 60% WT, 60% A-FABP^{-/-}) during *in vivo* studies and an *in vitro* tumor invasion study. Tumors were measured at 3-day intervals with calipers at two bisecting diameters and an approximate volume was calculated by the formula $\{(0.4) \times (\text{large diameter}) \times (\text{small diameter})^2\}$. Mice were sacrificed after 26 days. To prepare single cell suspensions, resected tumors were digested in a digestion mixture consisting of 5% FBS in RPMI 1640, 0.5mg/ml collagenase A (Roche Diagnostic), 0.2mg/ml hyaluronidase type V (Sigma-Aldrich), and 0.02mg/ml DNase I (Sigma-Aldrich) at 37°C for 30 minutes on a rotating platform. The resulting cell suspensions were filtered through 70µm cell strainers (BD Biosciences) and washed with 5% FBS in RPMI 1640. Cell debris/dead cells were removed by centrifugation with Lymphocyte-M (Cedarlane Laboratories) as recommended by the manufacturer. Tumor-infiltrating macrophages were purified by positive selection with anti-CD11b (Mac-1) magnetic beads (Miltenyi Biotec). A purity of >95% CD11b⁺ cells was confirmed by flow cytometry.

Generation of bone marrow-derived macrophages.

Bone marrow-derived macrophages were generated from wild-type and A-FABP^{-/-} mice. Briefly, femurs and tibias from 8-10 week old mice were flushed with DPBS and bone marrow was filtered and washed. Bone marrow was plated overnight in RPMI 1640 supplemented with 10ng/ml M-CSF (R&D Systems). After overnight incubation, non-adherent cells were plated in RPMI 1640 containing 25% filtered L929 fibroblast supernatants (ATCC) and 10ng/ml M-CSF in 6-well ultra low cluster plates (Corning). Cells were harvested on day 7 and purified by centrifugation on 35% Ficoll (Atlanta Biologicals). Macrophages were analyzed for CD11c, CD11b, CD80, CD86, CD40, and I-A^b expression by flow cytometry. Macrophages were consistently >98% CD11b⁺.

Flow Cytometric Analysis.

For cell composition of tumor, 10⁶ single cells were treated with Fc block (BD Biosciences) for 15 minutes prior to incubation with fluorochrome-conjugated anti-CD4, anti-CD8, anti-CD19, anti-CD11c, anti-CD11b, anti-F4/80, anti-NK1.1, and anti-Ly6G (all from BD Biosciences) for 30 minutes at 4°C. Samples were analyzed using a FACS Calibur flow cytometer and FlowJo Software (Tree Star Inc.).

Quantitative Real-time RT-PCR analysis. mRNA was isolated from 10⁶ purified tumor-infiltrating macrophages and converted to cDNA using MACS One-Step cDNA Columns (Miltenyi Biotec). Real-time RT-PCR was performed with a DNA-

Opticon 3 Monitor (Bio-Rad) using SYBR Green (Qiagen). MIF, MCP-1, CSF-1, VEGF, EGF, MMP-12, MMP-9, TNF α , TGF β , IL-6, IL-10, IL-12, IL-15, IL-23, FABP4, and β -actin expression was analyzed by Quantitect Primer Assays (Qiagen). Results were normalized to β -actin. Relative expression of RNA transcripts were quantified using the Relative Expression Software Tool, REST.

Western blot analysis.

10⁶ macrophages were lysed in buffer containing 25mM Tris-HCl, 1% deoxycholate, 0.35M NaCl, phosphatase inhibitor solution (Cayman Chemical), and 1% Triton X-100 (Fisher Scientific). Protein quantity was assayed by bicinchoninic acid (Pierce) and 12 μ g of protein was loaded per well on a 10% or 15% Tris-HCl gel (Bio-Rad). The contents of the gel were transferred onto nitrocellulose membranes (Amersham Biosciences) using a Trans-Blot SemiDry Transfer Cell (Bio-Rad). The membranes incubated with different antibodies. Antibody-bound proteins were detected using an ECL Western Blotting Analysis System (Amersham Biosciences), and the membranes were exposed to Kodak Biomax XL X-ray Film (Eastman Kodak).

Immunohistochemistry.

Tumors were excised and snap frozen in tissue freezing medium (OCT). Tissue blocks were cut and fixed with cold acetone. To detect intratumoral MMP-9 expression or tumor vascularization, the sections were first blocked with 2.5% BSA in 10X PBS, and then stained with biotinylated anti-MMP-9, anti-CD31 (R&D

Systems), or anti-MMP-12 (Santa Cruz) for 1 hour at room temperature. After washing, the sections were incubated with VECTASTAIN Elite ABC Reagent (Vector Laboratories) for 30 minutes. Sections were developed with peroxidase substrate solution DAB to desired stain intensity and counterstained with hematoxylin to provide morphologic detail. The images were taken and analyzed with Aperio Imagescope Software (Aperio Technologies).

Tumor Invasion Assay

CD11b⁺ TIMs were isolated from WT and A-FABP^{-/-} mice on a normal or high fat diet. 1×10^6 TIMs were seeded into the bottom chamber of the Fluoroblok Tumor Invasion System (BD Biosciences) in serum-free media. Serum-free media and media alone were used as negative and positive controls, respectively. 2.5×10^4 LL/2 cells were seeded in the top chamber in serum-free media. Tumor cells were allowed to invade through the 0.8 μ m Matrigel matrix for 20 hours at 37°C. Invaded tumor cells were then stained with calcien for 1 hour at 37°C. Fluorescence of invaded tumor cells was read at 494/517nm (Ex/Em) using a fluorescent plate reader (SoftMax Pro). Pictures of the fluorescent invaded tumor cells were taken with a fluorescent microscope (Evos). Magnification 20X.

Oil Red O Staining

Tumors were excised and snap frozen in tissue freezing medium (OCT). Tissue blocks were cut and fixed with 10% neutral buffered formalin for 10 minutes and then with propylene glycol for 2 minutes. To look at adipocyte infiltration, tumors

were stained with filtered Oil Red O 0.05% in propylene glycol (Poly Scientific) for 1 hour. After washing in distilled water, tumors were counterstained with Mayer's Modified Hematoxylin (Poly Scientific) for 30 seconds. Tumor stainings were preserved with Faramount Aqueous Mounting Medium (DAKO).

RESULTS

The Role of A-FABP in Tumor Growth and Metastasis

The tumor microenvironment enhances A-FABP expression in macrophages.

To determine the expression level of A-FABP in macrophages in response to tumor burden or the tumor microenvironment, WT mice were challenged with a subcutaneous injection of Lewis Lung Carcinoma (LL/2) cells, and after 26 days, CD11b⁺ macrophages were isolated from the spleen. WT mice without tumors were used as a control. RT-PCR analysis showed that splenic macrophages isolated from tumor-bearing mice had about a 20-fold increase in A-FABP mRNA levels compared to splenic macrophages taken from mice without a tumor (**Figure 7A**). Additionally, bone marrow-derived macrophages generated from WT mice were treated with LL/2 supernatant or media alone. These results also showed a significant increase in A-FABP mRNA levels in macrophages exposed to tumor supernatant (**Figure 7B**) when compared to unstimulated macrophages, suggesting that the tumor microenvironment is sufficient to induce A-FABP expression in macrophages.

A-FABP deficiency suppresses metastasis, but not tumor growth.

To elucidate the function of A-FABP in tumor growth and metastasis, mice with different levels of A-FABP expression were used (A-FABP^{+/+}, A-FABP^{+/-}, and A-FABP^{-/-}). Tumors grew at a similar rate between these groups of mice, and there was no difference in the tumor weight (**Figure 8**). However, there was a significant difference in metastasis, with WT mice averaging about 15 metastatic nodules in the liver and about 8 nodules in the lung, while little to no spots of metastasis were observed in A-FABP^{-/-} mice (**Figure 8**). A-FABP^{+/-} mice showed about a 50% reduction in metastatic nodules in both liver and lung as compared to WT mice (**Figure 8**). Taken together, this data shows that A-FABP deficiency protects mice from metastasis even at the same tumor growth rate.

A-FABP deficiency reduces the production of pro-inflammatory and metastasis-promoting proteins in tumor-infiltrating macrophages.

Metastasis is a multi-step process that involves proteins of the extracellular matrix, cytokines, chemokines, and growth factors. Many of these factors, including MMPs, EGF, CSF-1, and MCP-1, are secreted by tumor-infiltrating macrophages (TIMs), and are critical for in the induction of metastasis. To further confirm the role of A-FABP in metastasis, we observed the expression levels of various molecules involved in the metastatic process in CD11b⁺ TIMs isolated from WT and A-FABP^{-/-} mice. As shown in **Figure 9**, TIMs isolated from A-FABP^{-/-} mice had a 30-fold decrease in MMP-9 expression, 20-fold decrease in MMP-12 expression, and about a 10-fold decrease in MCP-1, CSF-1, and EGF

expression as compared to TIMs isolated from WT mice. Moreover, compared to WT TIMs, A-FABP^{-/-} TIMs showed reduced expression of TNF- α , IL-6, and IL-23, while exhibiting higher levels of anti-inflammatory proteins, TGF- β and IL-10 (**Figure 9B**). Bone marrow-derived macrophages from WT and A-FABP^{-/-} mice also exhibited similar gene expression levels after stimulation with LL/2 supernatant *in vitro* (data not shown). Additionally, staining of frozen tumor sections confirmed more MMP-9 and MMP-12 production in the tumor tissue from WT mice than that of A-FABP^{-/-} mice (**Figure 9C, 8D**). However, when tumor sections were stained with CD31 to observe blood vessel formation in LL/2 tumors, there were no statistical differences between WT and A-FABP^{-/-} mice (data not shown).

Use of a small molecule inhibitor of A-FABP also suppresses metastasis.

To further evaluate the function of A-FABP in suppressing metastasis, we employed a small molecule inhibitor of A-FABP, HTS01037 [148]. Oral feeding of HTS01037 did not affect tumor growth (**Figure 10B**), but it did suppress tumor metastasis to the lung (**Figure 10C, 10D**). Some inhibitor-treated mice exhibited similar numbers of metastatic nodules as compared to non-treated mice, but the size and intensity of the nodules were much less than control groups (**Figure 10C, 10D**). More importantly, TIMs isolated from inhibitor-treated mice showed a significant decrease in MMP-9 and MMP-12 gene expression levels compared to control mice (**Figure 10E**). When HTS01037 was added to *in vitro* cultured bone marrow-derived macrophages pre-stimulated with LL/2 supernatant, MMP-9 and

MMP-12 production was also reduced in a dose-dependent manner (**Figure 10A**). These data further demonstrate that A-FABP suppresses metastasis via impacting the production of metastasis-promoting proteins by TIMs.

Figure 7. Increased A-FABP expression in macrophages in response to the tumor microenvironment. *A*, Splenic macrophages isolated from tumor-bearing mice have increased mRNA levels of A-FABP when compared to splenic macrophages isolated from mice without a tumor. *B*, bone marrow-derived macrophages treated with tumor supernatant show higher mRNA levels of A-FABP compared to the untreated group (* $p = 0.001$).

Figure 8. A-FABP deficiency suppresses tumor metastasis. Compared to A-FABP^{+/+} mice, A-FABP heterozygous knockouts showed about a 50% reduction in lung and liver metastasis, which was reduced even further in A-FABP homozygous knockouts. A is graphical representation of B. (Conducted by Bing Li).

Figure 9. A-FABP deficient macrophages show decreased production of pro-inflammatory and metastasis-promoting proteins. A, RT-PCR analysis of TIM isolated from WT and A-FABP^{-/-} mice. Compared to WT mice, A-FABP^{-/-} show reduced expression of proteins involved in metastasis, including MMP-9, MMP-12, EGF, and CCL2; along with reduced expression of pro-inflammatory cytokines such as TNF- α and IL-6, and increased of expression of anti-inflammatory cytokines TGF- β and IL-10. B and C, Immunohistochemical analysis shows reduced expression of MMP-9 and MMP-12 in the tumor tissue of A-FABP^{-/-} mice compared to that of WT mice (* $p = 0.001$) (Conducted by Bing Li).

Figure 10. HTS01037, a small molecule inhibitor of A-FABP, reduces lung metastasis and MMP production, but has no effect on tumor growth. A, Bone marrow-derived macrophages from WT mice were treated with increasing concentrations of HTS01037. RT-PCR analysis shows that MMP-9 and MMP-12 mRNA levels decrease as the concentration of the inhibitor increases. *B through E,* WT mice were treated with HTS01037 or vehicle. *B,* Inhibition of A-FABP had no effect on tumor growth, however there was reduced lung metastasis in inhibitor-treated mice as compared to the control group (*C, D*). *E,* TIMs isolated from inhibitor-treated mice had reduced MMP-9 and MMP-12 production (Conducted by Bind Li).

The Role of A-FABP in Tumor Growth and Metastasis in Diet-Induced Obese Mice

A-FABP is not only increased in response to the tumor microenvironment, but it is also increased in response to high fat consumption.

Previous studies have demonstrated higher macrophage A-FABP levels in diet-induced obese mice compared to lean mice, as well increased expression in atherosclerotic lesions of obese mice compared to lean or healthy mice [137].

We have already shown significantly higher levels of A-FABP in splenic macrophages in response to the tumor microenvironment, but is this expression increased even more in obese tumor-bearing mice? Here, WT mice were fed a normal (10%) diet or high fat (60%) diet for 120 days prior to implantation of LL/2 cells. **Figure 11** shows that WT and A-FABP^{-/-} mice fed a high fat diet have similar weights. CD11b⁺ splenic macrophages and TIM taken from high fat-fed WT mice showed a significant increase in A-FABP expression when compared to splenic macrophages and TIMs isolated from mice fed a normal diet, respectively (**Figure 12**). These data along with results from **Figure 7** suggest that A-FABP expression level increases in response to both the tumor microenvironment and high fat consumption in macrophages.

A-FABP deficiency confers protection against tumor growth and metastasis in both lean and diet-induced obese mice.

Next, we observed the effect of A-FABP deficiency on tumor growth and metastasis under conditions of high fat feeding. There was no difference in tumor growth between WT and A-FABP^{-/-} mice fed a regular chow diet. There was also no observed difference in tumor growth in WT mice treated with an inhibitor of A-FABP when compared to the untreated group (**Figure 10**). This same trend was also observed in WT and A-FABP^{-/-} mice fed a normal (10%) diet, however when mice were placed on a high fat (60%) diet, WT mice showed a significant increase in tumor growth, while A-FABP^{-/-} mice fed a high fat diet displayed reduced tumor growth rates that were similar to those of lean mice (**Figure 13A**). The tumor weights correlated with tumor growth rates between each group of mice (**Figure 13B**).

We also observed lung metastasis in normal (10%) and high fat (60%) diet fed WT and A-FABP^{-/-} mice. WT mice on a normal diet averaged about 7 metastatic nodules, while WT mice on a high fat diet averaged about 12 metastatic nodules in the lung. A-FABP^{-/-} mice on normal or high fat diets showed a significant reduction in lung metastasis with an average of 2 and 4 metastatic nodules in the lung, respectively (**Figure 14**). To further determine the role of A-FABP in high fat consumption and metastasis, we assessed TIM-mediated tumor cell invasion using an *in vitro* tumor invasion assay. CD11b⁺ TIM isolated from WT and A-FABP^{-/-} mice on normal and high fat diets were seeded in the bottom chamber of the invasion system with LL/2 cells seeded in the top insert of the

invasion system. Tumor cells were allowed to invade the Matrigel matrix for 20 hours. As shown in **Figure 15**, TIMs isolated from high fat fed WT mice induced the highest level of tumor cell invasion, followed by TIM from normal diet fed mice. TIMs taken from A-FABP^{-/-} mice fed either diet showed a reduction in the ability to induce tumor cell invasion. These data are also consistent with the *in vivo* lung metastasis data (**Figure 15**).

Tumors from high fat fed WT mice show an increase in macrophage infiltration.

To determine the immune cell composition of WT and A-FABP^{-/-} tumors, single cell suspensions were generated and used in flow cytometric analysis. Compared to tumors from normal diet fed WT mice, there was no significant difference in CD8⁺ T cell, B cell, or NK cell infiltrates in each group of mice (**Figure 16 C-E**). However, there was significant increase in macrophage infiltration in tumors from high fat fed WT mice (**Figure 16A**) along with an increase in CD4⁺ T cells (**Figure 16B**). Surprisingly, there was also a significant increase in CD4⁺ T cells in high fat fed A-FABP^{-/-} mice (**Figure 16B**). Whether these CD4⁺ cells found in high fat fed WT and A-FABP^{-/-} tumors were CD25⁺Foxp3⁺ or CD25⁺Foxp3⁻ was not determined.

A-FABP deficiency, despite a normal or high fat diet, decreases the production of pro-inflammatory cytokines and proteins involved in metastasis.

Next we determined the cytokine profile of TIM isolated from WT and A-FABP^{-/-} mice fed a high fat diet. Relative to TIM isolated from normal diet fed WT mice, TIM from high fat fed WT mice showed an increase in several proteins involved in metastasis, including MIF, VEGF, and MMP-9, which may explain why more metastatic nodules were observed in these mice. Conversely, TIM taken from A-FABP^{-/-} mice fed a high fat diet showed a reduction in metastasis-promoting proteins and pro-inflammatory cytokines, while increased mRNA levels of anti-inflammatory cytokines, TGF- β and IL-10 (**Figure 17**). These data are in conjunction with the cytokine profile shown in Figure 9, suggesting that A-FABP deficiency can promote an anti-tumoral phenotype in macrophages despite dietary conditions. In the diet-induced obese models, there was a drastic increase in CCL2 mRNA levels. This chemokine has been implicated in the recruitment of macrophages to the adipose tissue in obese mice and humans [7]. Compared to WT mice on a normal diet, TIM isolated from high fat fed WT mice had about a 7000-fold increase in CCL2 followed by a 2000-fold increase in TIM from high fat-fed A-FABP^{-/-} (**Figure 17B**). These data suggest that despite the increase in CCL2 levels, which seems to correlate with increased macrophage recruitment in tumors of high fat fed mice (will be discussed later in Figure 16), A-FABP^{-/-} TIM still display an anti-tumoral phenotype, indicating that it is the activation state rather than quantity that influences the LL/2 tumor outcome.

We also looked at the expression of the metastasis-promoting protein, MMP-9, in the tumor tissue as well as TIM by Western blot (**Figure 19 and 18, respectively**). When compared to normal diet or high fat diet fed WT mice, A-

FABP^{-/-} mice showed reduced MMP expression on either diet. Moreover, CD31, an endothelial cell marker, was also observed in the tumor tissue. Although there was no difference in the expression in normal diet fed WT and A-FABP^{-/-} mice (data not shown), there was a significant reduction in CD31 expression in A-FABP^{-/-} mice on a high fat diet relative to high fat fed WT mice (**Figure 19**). Using an Oil Red O stain, we were able to look at lipid deposition in the tumor. As expected, it appears to be lipid deposits in the tumors of high fat fed WT and A-FABP^{-/-} mice compared to normal diet fed mice (**Figure 20**). However, the role of these cells in our model has not been explored.

Several studies have demonstrated the requirement of NF-κB activation in macrophages for cancer progression [149, 150]. NF-κB activation in macrophages has been shown to trigger the release of a variety of cytokines including TNF-α and IL-6, which induce pro-survival signals in tumor cells. Additionally, these macrophages also release metastasis-promoting proteins including VEGF and CSF-1, which support malignant progression and tumor growth. Here, we evaluated the activation status of NF-κB in TIM. Compared to TIM isolated from high fat fed WT mice, A-FABP^{-/-} on the same diet displayed a drastic reduction in the phosphorylation of the p65 subunit of NF-κB (**Figure 21**). These data complement those in **Figure 17**, as this may be why there is reduced expression of metastasis-promoting proteins and pro-inflammatory cytokines in TIM from A-FABP^{-/-} mice.

Figure 11. Weight of WT and A-FABP^{-/-} mice fed a normal or high fat diet.

Weight of WT and A-FABP^{-/-} mice fed a normal or high fat diet was taken before and after tumor implantation. High fat fed A-FABP^{-/-} mice have weights that are similar to WT mice on the same diet.

Figure 12. A-FABP expression in lean versus diet-induced obese mice.
Splenic macrophages (A) and TIM (B) isolated from high fat fed WT mice show higher mRNA levels of A-FABP compared to lean counterparts (* $p = 0.001$).

Figure 13. A-FABP deficiency protects against tumor growth in mice fed a high fat diet. High fat fed wild-type mice had a significant increase in tumor growth (A) and weight (B), whereas A-FABP^{-/-} mice on the same diet had tumor growth rates and weight that were very similar to that of lean mice.

Figure 14. Lung metastasis in WT and A-FABP^{-/-} mice fed a normal or high fat diet. Relative to normal diet fed WT mice, high fat fed WT mice showed a significant increase in metastasis to the lung, which can be reduced in A-FABP deficient mice fed either diet.

Figure 15. TIM-induced invasion of LL/2 cells. *A*, an *in vitro* tumor invasion assay was performed by seeding TIM from WT and A-FABP^{-/-} mice on a normal or high fat diet in the bottom chamber of the invasion system and LL/2 tumor cells in the top chamber. Tumor cells were allowed to invade a Matrigel matrix for 20 hours. Tumor cells that did invade were stained with a fluorescent dye, calcien. *B*, quantification of calcien-stained tumor cells that invaded through the Matrigel matrix mediated by tumor-infiltrating macrophages.

Figure 15. C, Fluorescent microscopy images of LL/2 tumor cells that invaded through the Matrigel matrix mediated by tumor-infiltrating macrophages.

Figure 16. Composition of immune cell infiltration in tumors from WT and A-FABP^{-/-} mice on a normal or high fat diet. Single cell suspensions of tumors from WT and A-FABP^{-/-} mice fed a normal or high fat diet were used to elucidate the composition of the immune cell infiltrate by flow cytometry. There was no significant difference in CD8⁺ T cell, B cell, and NK cell infiltrates between each

group of mice, however, there was a significant increase in $CD4^+$ T cells in tumors from high fat fed WT and A-FABP^{-/-} mice, as well as F4/80⁺CD11b⁺ macrophages from high fat fed WT mice relative to tumors from normal diet fed WT mice.

A.

B.

Figure 17. TIM from normal and high fat diet fed A-FABP deficient mice show decreased production of pro-inflammatory and metastasis-promoting proteins. RT-PCR analysis of TIM isolated from WT and A-FABP^{-/-} mice fed a normal or high fat diet. A, compared to normal diet fed WT mice, TIM isolated from A-FABP^{-/-} mice show reduced expression of proteins involved in metastasis and pro-inflammatory cytokines while displaying increased of expression of anti-

inflammatory cytokines TGF- β and IL-10. In contrast, TIM from high fat fed WT mice display increased mRNA levels of MMP-9, VEGF, and MIF (* p = 0.001). *B*, moreover, compared to TIM from normal diet fed WT mice, TIM from both high fat fed WT and A-FABP^{-/-} mice show a dramatic increase in CCL2 expression (* p = 0.001).

Figure 18. Decreased protein expression of MMP-9 in TIM from A-FABP^{-/-} mice. Protein lysates taken from WT and A-FABP^{-/-} mice fed a normal (A) or high fat diet (B) were used to examine at MMP-9 expression by Western blot. Compared to WT TIM, TIM isolated from A-FABP^{-/-} mice display reduced protein expression of MMP-9.

Figure 19. Immunohistochemical staining in WT and A-FABP^{-/-} tumors. A, MMP-9 expression in tumor tissue. Compared to WT on a normal of high fat diet, A-FABP^{-/-} tumors showed a significant reduction of in MMP-9 expression on either diet. **B,** CD31 expression in tumor tissue. Tumors from high fat fed A-FABP^{-/-} mice showed reduced CD31 expression and vascularization than tumor from WT mice.

Figure 20. Lipid deposition in WT and A-FABP^{-/-} tumors from normal and high fat diet fed mice. Using an Oil Red O stain, lipid deposition was observed in the tumors displaying a more intense stain in tumors from high fat fed WT and A-FABP^{-/-} mice when compared to mice fed a normal diet.

Figure 21. NF-κB activation in TIM taken from WT and A-FABP^{-/-} fed a high fat diet. Protein lysates taken from WT and A-FABP^{-/-} mice fed a high fat diet were used to look at NF-κB expression by Western blot TIM isolated from diet-induced obese A-FABP^{-/-} mice show significant phosphorylation of p65 when compared to TIM from WT mice.

DISCUSSION

The obesity epidemic in the United States is steadily increasing. Currently, about two thirds of the adult population in the U.S. is considered to be obese [151], and parallel to this are increasing rates of obesity-related cancer deaths [93]. These statistics demonstrate the urgent need to understand the mechanisms of obesity-associated cancer progression. In the current study, we identify a factor that appears to serve as a link between high fat consumption and cancer progression, A-FABP.

Herein, we demonstrate a contribution of host A-FABP expression towards tumor metastasis and present evidence that A-FABP expression in macrophages facilitates the acquisition of tumor-promoting functions induced via macrophage-tumor interactions. Moreover, our findings suggest that under conditions of high fat feeding, A-FABP exacerbates the acquired tumor-promoting functions of macrophages. In the normal (10%) diet LL/2 model, tumor metastasis was consistently lower in A-FABP^{-/-} mice despite equivalent tumor growth kinetics, indicating that the effect on metastasis was unrelated to tumor burden. However, in the high fat (60%) diet model, lower metastasis appeared to be related to reduced tumor load and vascularization, suggesting that A-FABP deficiency may have an enhanced protective effect in diet-induced obese mice.

Since the expression of A-FABP is largely limited to adipocytes and mature myeloid cells, including macrophages and dendritic cells, we focused the study on macrophages as likely contributors to the observed phenomenon. We found that TIM isolated from both normal and high fat diet fed A-FABP^{-/-} mice displayed reduced expression levels of proteins involved in inflammation and metastasis while up-regulating genes that are anti-inflammatory. Many studies suggest that the tumor-supporting functions of macrophages are due to an alternatively activated, M2-like phenotype. It is this phenotype that promotes cancer progression via remodeling of the extracellular matrix and angiogenesis [152, 153]. In our normal and high fat diet LL/2 model, A-FABP^{-/-} TIM did display up-regulated M2-like genes, including TGF- β and IL-10. However, several other genes that contribute to the alternatively activated phenotype, including MMP-9, MMP-12, and VEGF were significantly down-regulated, conducive to tumor regression, and further demonstrating that macrophages employ a spectrum of activation phenotypes rather than distinct subsets. Additionally, many studies have focused on the immunosuppressive effects of IL-10 in the tumor microenvironment, however IL-10 also exerts some immunostimulatory effects, such as activation of B cells, induction of cytotoxic T lymphocytes, and up-regulation of genes in TLR-activated dendritic cells and macrophages [154-157]. IL-10 secretion from A-FABP deficient TIM may also be a contributing factor in reduced tumor growth and metastasis by influencing several other infiltrating immune cells. The effects of IL-10 in the A-FABP^{-/-} tumor model is an ongoing effort in our lab.

As mentioned previously, A-FABP deficiency is associated with increased PPAR- γ activity [109]. PPAR- γ has been shown to induce cell growth arrest, apoptosis, and differentiation in many cancer types including breast, lung, colon,

gastric, and prostate cancers [158, 159]. In immune cells, PPAR- γ regulates inflammatory gene transcription. Several cytokines including IL-6 and TNF- α have been implicated in the progression of several types of cancer, and studies show that PPAR- γ agonists, which have been shown to have therapeutic potential in the treatment of inflammatory and metabolic disease as well as cancer, can suppress the expression of these cytokines via inhibition of NF- κ B or C/EBP β [159, 160]. In our model, A-FABP deficiency down-regulates several inflammatory genes, which is likely due to PPAR- γ -mediated transrepression of NF- κ B. Activators of PPAR- γ have also been shown to inhibit MMP-9 expression in human bronchial epithelial cells as well as MMP-12 in macrophages [161]. Furthermore, activation of PPAR- γ represses VEGF expression in human endometrial cells and reduce serum VEGF levels in diet-induced insulin resistant mice [162, 163]. Thus, enhanced PPAR- γ activation in TIMs from A-FABP deficient mice may also suppress MMP and VEGF expression in addition to other pro-inflammatory mediators, thereby contributing to reduced lung and liver metastasis and to tumor regression. Additionally, we have previously shown that PPAR- γ up-regulates genes involved in cholesterol trafficking. Several published studies have demonstrated that tumor-infiltrating macrophages can take on a foam cell phenotype as seen in atherosclerosis [164]. In the diet-induced obese A-FABP deficient model, PPAR- γ activation may allow for the transport of cholesterol out of the cell, thus contributing to anti-inflammation.

We have also found that macrophages isolated from healthy A-FABP^{-/-} mice have increased levels of phosphorylated AMP-activated kinase α 1, AMPK- α 1 (data not shown). Additionally, we, and others, have found that in an obese state, AMPK, which also promotes anti-inflammatory gene expression, is down-regulated while A-FABP expression levels are increased [165]. This phenomenon

may contribute to the polarized pro-inflammatory phenotype found in macrophages bathed in an environment of metabolic excess. AMPK is a metabolic sensor that, upon activation, inhibits energy-consuming processes and promote ATP-producing pathways [166]. AMPK activation has been shown to provide protection against tumor growth and metastasis in both mice and diabetic humans [167, 168]. Moreover, the anti-diabetic drug, metformin, which has gained recent interest in the treatment of cancer, is a potent activator of AMPK. Because AMPK has been shown to suppress various proteins involved in metastasis, including MMP-9 [167, 169], it may also serve as an additional mechanism by which A-FABP deficiency suppresses tumor growth and metastasis in both lean and obese mice. Furthermore, both A-FABP deficiency and AMPK activation improves insulin sensitivity and reduces circulating levels of insulin, which may also contribute to tumor regression, particularly in diet-induced obese mice.

Several studies have shown that tumor-infiltrating adipocytes display an activated phenotype and are capable of inducing cancer cell proliferation, migration, and invasion [170-172]. Neiman and colleagues further showed that the tumor-promoting functions of adipocytes could be attributed to A-FABP expression [144]. Because A-FABP is expressed in both adipocytes and macrophages, it is possible that the effect of A-FABP knockdown on tumor progression can be attributed to functions in both cell types, especially since we are using a whole animal knockout. In a model of atherosclerosis, Boord and colleagues conducted a bone marrow transplantation study to determine if the effects of A-FABP expression was due to its function in macrophages or adipocytes. When bone marrow from A-FABP^{-/-} ApoE^{-/-} mice were transferred into ApoE^{-/-} mice, less atherosclerosis developed, suggesting that it was the

expression of A-FABP in macrophages and not adipocytes that contributed to disease progression [138]. This may also be the case in our LL/2 tumor model. With the recent development of macrophage-specific A-FABP conditional knockout mice available at the Jackson Laboratory, this question can soon be addressed.

In addition to adipocytes, dendritic cells, and macrophages, A-FABP has recently been shown to be expressed in endothelial cells of capillaries and small veins in both mouse and human tissue [173]. Studies illustrate that A-FABP expression is induced by treatment with VEGF-A and basic fibroblast growth factor (bFGF) via VEGF receptor-2 (VEGFR2). A-FABP knockdown in endothelial cells resulted in decreased proliferation of these cells in both untreated and VEGF-A- and bFGF-treated cells, suggesting that A-FABP induces endothelial cell proliferation via the VEGF-A/VEGFR2 pathway [173]. Further studies demonstrated that chronic administration of an A-FABP inhibitor, BMS309403, improved endothelial cells dysfunction in ApoE deficient mice significantly [174]. Although no one has shown A-FABP expression in tumor-associated endothelial cells, it very well may be the case since protein expression in tumors are dysregulated. This is another avenue of the role of A-FABP in cancer progression to be explored. Inhibition of A-FABP would not only suppress the tumor-promoting functions of macrophages and adipocytes, but it could possibly lead to a significant reduction in angiogenesis via inhibition of endothelial cell proliferation.

In this study, we show a role of A-FABP in cancer progression, while deletion of this protein protects against tumor growth and metastasis. We also demonstrate the importance of A-FABP in the link between high fat consumption and cancer progression. Moreover, by using a lung cancer model, (past and

recent data suggests that obesity does not affect the development and advancement of lung cancer [175]) we were able to show that dietary conditions can impact the progression of this type of cancer. Our data, along with the finding that A-FABP deficiency is protective against atherosclerosis, insulin resistance, and type 2 diabetes, indicates that inhibition of A-FABP may be utilized as a novel approach in treating inflammatory and metabolic disorders, as well as cancer that is associated and unassociated with obesity. Moreover, because agonists of AMPK and PPAR- γ have been implicated in cancer therapy, it may be more useful to inhibit A-FABP to activate AMPK and PPAR- γ simultaneously, which may induce an enhanced therapeutic effect.

REFERENCES

1. Lysaght, J., et al., *Pro-inflammatory and tumour proliferative properties of excess visceral adipose tissue*. Cancer letters, 2011. **312**(1): p. 62-72.
2. Park, E.J., et al., *Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression*. Cell, 2010. **140**(2): p. 197-208.
3. Lewis, C.E. and J.W. Pollard, *Distinct role of macrophages in different tumor microenvironments*. Cancer research, 2006. **66**(2): p. 605-12.
4. Coussens, L.M. and Z. Werb, *Inflammation and cancer*. Nature, 2002. **420**(6917): p. 860-7.
5. Dalmas, E., K. Clement, and M. Guerre-Millo, *Defining macrophage phenotype and function in adipose tissue*. Trends in immunology, 2011. **32**(7): p. 307-14.
6. Xu, H., et al., *Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance*. The Journal of clinical investigation, 2003. **112**(12): p. 1821-30.
7. Weisberg, S.P., et al., *Obesity is associated with macrophage accumulation in adipose tissue*. The Journal of clinical investigation, 2003. **112**(12): p. 1796-808.
8. Condeelis, J. and J.W. Pollard, *Macrophages: obligate partners for tumor cell migration, invasion, and metastasis*. Cell, 2006. **124**(2): p. 263-6.
9. Mantovani, A., et al., *Role of tumor-associated macrophages in tumor progression and invasion*. Cancer metastasis reviews, 2006. **25**(3): p. 315-22.
10. Lin, E.Y. and J.W. Pollard, *Tumor-associated macrophages press the angiogenic switch in breast cancer*. Cancer research, 2007. **67**(11): p. 5064-6.
11. Sica, A., *Role of tumour-associated macrophages in cancer-related inflammation*. Experimental oncology, 2010. **32**(3): p. 153-8.
12. Chen, J., et al., *CCL18 from tumor-associated macrophages promotes breast cancer metastasis via PITPNM3*. Cancer cell, 2011. **19**(4): p. 541-55.
13. Geissmann, F., et al., *Development of monocytes, macrophages, and dendritic cells*. Science, 2010. **327**(5966): p. 656-61.
14. Murray, P.J. and T.A. Wynn, *Protective and pathogenic functions of macrophage subsets*. Nature reviews. Immunology, 2011. **11**(11): p. 723-37.

15. Hashimoto, D., J. Miller, and M. Merad, *Dendritic cell and macrophage heterogeneity in vivo*. Immunity, 2011. **35**(3): p. 323-35.
16. Mosser, D.M. and J.P. Edwards, *Exploring the full spectrum of macrophage activation*. Nature reviews. Immunology, 2008. **8**(12): p. 958-69.
17. Taylor, P.R. and S. Gordon, *Monocyte heterogeneity and innate immunity*. Immunity, 2003. **19**(1): p. 2-4.
18. Stout, R.D. and J. Suttles, *Functional plasticity of macrophages: reversible adaptation to changing microenvironments*. Journal of leukocyte biology, 2004. **76**(3): p. 509-13.
19. Nguyen, K.D., et al., *Alternatively activated macrophages produce catecholamines to sustain adaptive thermogenesis*. Nature, 2011. **480**(7375): p. 104-8.
20. Lee, S.J., et al., *HNE-induced 5-LO expression is regulated by NF- κ B/ERK and Sp1/p38 MAPK pathways via EGF receptor in murine macrophages*. Cardiovascular research, 2010. **88**(2): p. 352-9.
21. Yun, M.R., et al., *5-Lipoxygenase plays an essential role in 4-HNE-enhanced ROS production in murine macrophages via activation of NADPH oxidase*. Free radical research, 2010. **44**(7): p. 742-50.
22. Bhargava, P. and C.H. Lee, *Role and function of macrophages in the metabolic syndrome*. The Biochemical journal, 2012. **442**(2): p. 253-62.
23. Mogilenko, D.A., et al., *Modified Low Density Lipoprotein Stimulates Complement C3 Expression and Secretion via Liver X Receptor and Toll-like Receptor 4 Activation in Human Macrophages*. The Journal of biological chemistry, 2012. **287**(8): p. 5954-68.
24. Stout, R.D. and J. Suttles, *Immunosenescence and macrophage functional plasticity: dysregulation of macrophage function by age-associated microenvironmental changes*. Immunological reviews, 2005. **205**: p. 60-71.
25. O'Shea, J.J. and P.J. Murray, *Cytokine signaling modules in inflammatory responses*. Immunity, 2008. **28**(4): p. 477-87.
26. Lawrence, T. and G. Natoli, *Transcriptional regulation of macrophage polarization: enabling diversity with identity*. Nature reviews. Immunology, 2011. **11**(11): p. 750-61.
27. Dale, D.C., L. Boxer, and W.C. Liles, *The phagocytes: neutrophils and monocytes*. Blood, 2008. **112**(4): p. 935-45.
28. Yamamoto, M., et al., *Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway*. Science, 2003. **301**(5633): p. 640-3.
29. Langrish, C.L., et al., *IL-23 drives a pathogenic T cell population that induces autoimmune inflammation*. The Journal of experimental medicine, 2005. **201**(2): p. 233-40.
30. Bettelli, E., et al., *Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells*. Nature, 2006. **441**(7090): p. 235-8.
31. Kolls, J.K. and A. Linden, *Interleukin-17 family members and inflammation*. Immunity, 2004. **21**(4): p. 467-76.

32. Szekanecz, Z. and A.E. Koch, *Macrophages and their products in rheumatoid arthritis*. Current opinion in rheumatology, 2007. **19**(3): p. 289-95.
33. Zhang, X. and D.M. Mosser, *Macrophage activation by endogenous danger signals*. The Journal of pathology, 2008. **214**(2): p. 161-78.
34. Gordon, S. and F.O. Martinez, *Alternative activation of macrophages: mechanism and functions*. Immunity, 2010. **32**(5): p. 593-604.
35. Varin, A., et al., *Alternative activation of macrophages by IL-4 impairs phagocytosis of pathogens but potentiates microbial-induced signalling and cytokine secretion*. Blood, 2010. **115**(2): p. 353-62.
36. Martinez, F.O., et al., *Macrophage activation and polarization*. Frontiers in bioscience : a journal and virtual library, 2008. **13**: p. 453-61.
37. Stout, R.D., S.K. Watkins, and J. Suttles, *Functional plasticity of macrophages: in situ reprogramming of tumor-associated macrophages*. Journal of leukocyte biology, 2009. **86**(5): p. 1105-9.
38. Benoit, M., B. Desnues, and J.L. Mege, *Macrophage polarization in bacterial infections*. Journal of immunology, 2008. **181**(6): p. 3733-9.
39. Mege, J.L., V. Mehraj, and C. Capo, *Macrophage polarization and bacterial infections*. Current opinion in infectious diseases, 2011. **24**(3): p. 230-4.
40. Takahashi, K., M. Takeya, and N. Sakashita, *Multifunctional roles of macrophages in the development and progression of atherosclerosis in humans and experimental animals*. Medical electron microscopy : official journal of the Clinical Electron Microscopy Society of Japan, 2002. **35**(4): p. 179-203.
41. Kamada, N., et al., *Unique CD14 intestinal macrophages contribute to the pathogenesis of Crohn disease via IL-23/IFN-gamma axis*. The Journal of clinical investigation, 2008. **118**(6): p. 2269-80.
42. Hendriks, J.J., et al., *Macrophages and neurodegeneration*. Brain research. Brain research reviews, 2005. **48**(2): p. 185-95.
43. Sica, A. and V. Bronte, *Altered macrophage differentiation and immune dysfunction in tumor development*. The Journal of clinical investigation, 2007. **117**(5): p. 1155-66.
44. Hanahan, D. and R.A. Weinberg, *Hallmarks of cancer: the next generation*. Cell, 2011. **144**(5): p. 646-74.
45. Mantovani, A., et al., *Cancer-related inflammation*. Nature, 2008. **454**(7203): p. 436-44.
46. Mantovani, A., C. Garlanda, and P. Allavena, *Molecular pathways and targets in cancer-related inflammation*. Annals of medicine, 2010. **42**(3): p. 161-70.
47. Leek, R.D., et al., *Necrosis correlates with high vascular density and focal macrophage infiltration in invasive carcinoma of the breast*. British journal of cancer, 1999. **79**(5-6): p. 991-5.
48. Lissbrant, I.F., et al., *Tumor associated macrophages in human prostate cancer: relation to clinicopathological variables and survival*. International journal of oncology, 2000. **17**(3): p. 445-51.

49. Hanada, T., et al., *Prognostic value of tumor-associated macrophage count in human bladder cancer*. International journal of urology : official journal of the Japanese Urological Association, 2000. **7**(7): p. 263-9.
50. Hamada, I., et al., *Clinical effects of tumor-associated macrophages and dendritic cells on renal cell carcinoma*. Anticancer research, 2002. **22**(6C): p. 4281-4.
51. Koide, N., et al., *Significance of macrophage chemoattractant protein-1 expression and macrophage infiltration in squamous cell carcinoma of the esophagus*. The American journal of gastroenterology, 2004. **99**(9): p. 1667-74.
52. Sica, A., P. Allavena, and A. Mantovani, *Cancer related inflammation: the macrophage connection*. Cancer letters, 2008. **267**(2): p. 204-15.
53. Lazennec, G. and A. Richmond, *Chemokines and chemokine receptors: new insights into cancer-related inflammation*. Trends in molecular medicine, 2010. **16**(3): p. 133-44.
54. Allavena, P., et al., *Chemokines in cancer related inflammation*. Experimental cell research, 2011. **317**(5): p. 664-73.
55. Lin, E.Y., et al., *Macrophages regulate the angiogenic switch in a mouse model of breast cancer*. Cancer research, 2006. **66**(23): p. 11238-46.
56. Lin, E.Y., et al., *Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy*. The Journal of experimental medicine, 2001. **193**(6): p. 727-40.
57. Lamagna, C., M. Aurrand-Lions, and B.A. Imhof, *Dual role of macrophages in tumor growth and angiogenesis*. Journal of leukocyte biology, 2006. **80**(4): p. 705-13.
58. Voronov, E., et al., *IL-1 is required for tumor invasiveness and angiogenesis*. Proceedings of the National Academy of Sciences of the United States of America, 2003. **100**(5): p. 2645-50.
59. Leibovich, S.J., et al., *Macrophage-induced angiogenesis is mediated by tumour necrosis factor-alpha*. Nature, 1987. **329**(6140): p. 630-2.
60. Koch, A.E., et al., *Interleukin-8 as a macrophage-derived mediator of angiogenesis*. Science, 1992. **258**(5089): p. 1798-801.
61. Tjiu, J.W., et al., *Tumor-associated macrophage-induced invasion and angiogenesis of human basal cell carcinoma cells by cyclooxygenase-2 induction*. The Journal of investigative dermatology, 2009. **129**(4): p. 1016-25.
62. Nakamura, T., et al., *Stromal metalloproteinase-9 is essential to angiogenesis and progressive growth of orthotopic human pancreatic cancer in parabiont nude mice*. Neoplasia, 2007. **9**(11): p. 979-86.
63. Leek, R.D., et al., *Macrophage infiltration is associated with VEGF and EGFR expression in breast cancer*. The Journal of pathology, 2000. **190**(4): p. 430-6.
64. Leek, R.D., et al., *Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma*. Cancer research, 1996. **56**(20): p. 4625-9.

65. Pugh, C.W. and P.J. Ratcliffe, *Regulation of angiogenesis by hypoxia: role of the HIF system*. Nature medicine, 2003. **9**(6): p. 677-84.
66. Green, C.E., et al., *Chemoattractant signaling between tumor cells and macrophages regulates cancer cell migration, metastasis and neovascularization*. PloS one, 2009. **4**(8): p. e6713.
67. Joyce, J.A. and J.W. Pollard, *Microenvironmental regulation of metastasis*. Nature reviews. Cancer, 2009. **9**(4): p. 239-52.
68. Pollard, J.W., *Macrophages define the invasive microenvironment in breast cancer*. Journal of leukocyte biology, 2008. **84**(3): p. 623-30.
69. Wyckoff, J.B., et al., *Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors*. Cancer research, 2007. **67**(6): p. 2649-56.
70. Condeelis, J. and J.E. Segall, *Intravital imaging of cell movement in tumours*. Nature reviews. Cancer, 2003. **3**(12): p. 921-30.
71. Ingman, W.V., et al., *Macrophages promote collagen fibrillogenesis around terminal end buds of the developing mammary gland*. Developmental dynamics : an official publication of the American Association of Anatomists, 2006. **235**(12): p. 3222-9.
72. Chawla, A., K.D. Nguyen, and Y.P. Goh, *Macrophage-mediated inflammation in metabolic disease*. Nature reviews. Immunology, 2011. **11**(11): p. 738-49.
73. Cinti, S., et al., *Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans*. Journal of lipid research, 2005. **46**(11): p. 2347-55.
74. Lumeng, C.N., et al., *Phenotypic switching of adipose tissue macrophages with obesity is generated by spatiotemporal differences in macrophage subtypes*. Diabetes, 2008. **57**(12): p. 3239-46.
75. Odegaard, J.I., et al., *Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance*. Nature, 2007. **447**(7148): p. 1116-20.
76. Olefsky, J.M. and C.K. Glass, *Macrophages, inflammation, and insulin resistance*. Annual review of physiology, 2010. **72**: p. 219-46.
77. Hotamisligil, G.S., *Inflammatory pathways and insulin action*. International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity, 2003. **27 Suppl 3**: p. S53-5.
78. Shibata, N. and C.K. Glass, *Regulation of macrophage function in inflammation and atherosclerosis*. Journal of lipid research, 2009. **50 Suppl**: p. S277-81.
79. Weisberg, S.P., et al., *CCR2 modulates inflammatory and metabolic effects of high-fat feeding*. The Journal of clinical investigation, 2006. **116**(1): p. 115-24.
80. Kanda, H., et al., *MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity*. The Journal of clinical investigation, 2006. **116**(6): p. 1494-505.

81. Patsouris, D., et al., *Ablation of CD11c-positive cells normalizes insulin sensitivity in obese insulin resistant animals*. Cell metabolism, 2008. **8**(4): p. 301-9.
82. Arkan, M.C., et al., *IKK-beta links inflammation to obesity-induced insulin resistance*. Nature medicine, 2005. **11**(2): p. 191-8.
83. Solinas, G., et al., *JNK1 in hematopoietically derived cells contributes to diet-induced inflammation and insulin resistance without affecting obesity*. Cell metabolism, 2007. **6**(5): p. 386-97.
84. Oh, D.Y., et al., *GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects*. Cell, 2010. **142**(5): p. 687-98.
85. Konner, A.C. and J.C. Bruning, *Toll-like receptors: linking inflammation to metabolism*. Trends in endocrinology and metabolism: TEM, 2011. **22**(1): p. 16-23.
86. Shi, H., et al., *TLR4 links innate immunity and fatty acid-induced insulin resistance*. The Journal of clinical investigation, 2006. **116**(11): p. 3015-25.
87. Hosoi, T., et al., *Myeloid differentiation factor 88 (MyD88)-deficiency increases risk of diabetes in mice*. PloS one, 2010. **5**(9).
88. Saberi, M., et al., *Hematopoietic cell-specific deletion of toll-like receptor 4 ameliorates hepatic and adipose tissue insulin resistance in high-fat-fed mice*. Cell metabolism, 2009. **10**(5): p. 419-29.
89. Poggi, M., et al., *C3H/HeJ mice carrying a toll-like receptor 4 mutation are protected against the development of insulin resistance in white adipose tissue in response to a high-fat diet*. Diabetologia, 2007. **50**(6): p. 1267-76.
90. Tsukumo, D.M., et al., *Loss-of-function mutation in Toll-like receptor 4 prevents diet-induced obesity and insulin resistance*. Diabetes, 2007. **56**(8): p. 1986-98.
91. Calle, E.E. and R. Kaaks, *Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms*. Nature reviews. Cancer, 2004. **4**(8): p. 579-91.
92. Wu, A.H., P. Wan, and L. Bernstein, *A multiethnic population-based study of smoking, alcohol and body size and risk of adenocarcinomas of the stomach and esophagus (United States)*. Cancer causes & control : CCC, 2001. **12**(8): p. 721-32.
93. Calle, E.E., et al., *Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults*. The New England journal of medicine, 2003. **348**(17): p. 1625-38.
94. Bergstrom, A., et al., *Obesity and renal cell cancer--a quantitative review*. British journal of cancer, 2001. **85**(7): p. 984-90.
95. Pan, S.Y., et al., *Association of obesity and cancer risk in Canada*. American journal of epidemiology, 2004. **159**(3): p. 259-68.
96. Hu, J., Y. Mao, and K. White, *Overweight and obesity in adults and risk of renal cell carcinoma in Canada*. Sozial- und Praventivmedizin, 2003. **48**(3): p. 178-85.

97. Petrelli, J.M., et al., *Body mass index, height, and postmenopausal breast cancer mortality in a prospective cohort of US women*. Cancer causes & control : CCC, 2002. **13**(4): p. 325-32.
98. Kaaks, R., A. Lukanova, and M.S. Kurzer, *Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review*. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2002. **11**(12): p. 1531-43.
99. *IARC Handbooks of Cancer Prevention. Weight Control and Physical Activity in International Agency for Research on Cancer* 2002.
100. Amling, C.L., et al., *Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy*. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004. **22**(3): p. 439-45.
101. Freedland, S.J., et al., *Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: a report by the Shared Equal Access Regional Cancer Hospital database study group*. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004. **22**(3): p. 446-53.
102. Subbaramaiah, K., et al., *Obesity is associated with inflammation and elevated aromatase expression in the mouse mammary gland*. Cancer prevention research, 2011. **4**(3): p. 329-46.
103. Rose, D.P., D. Komninou, and G.D. Stephenson, *Obesity, adipocytokines, and insulin resistance in breast cancer*. Obesity reviews : an official journal of the International Association for the Study of Obesity, 2004. **5**(3): p. 153-65.
104. Cowey, S. and R.W. Hardy, *The metabolic syndrome: A high-risk state for cancer?* The American journal of pathology, 2006. **169**(5): p. 1505-22.
105. Brown, J.R. and R.N. DuBois, *COX-2: a molecular target for colorectal cancer prevention*. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005. **23**(12): p. 2840-55.
106. Lin, W.W. and M. Karin, *A cytokine-mediated link between innate immunity, inflammation, and cancer*. The Journal of clinical investigation, 2007. **117**(5): p. 1175-83.
107. Sonnenberg, G.E., G.R. Krakower, and A.H. Kissebah, *A novel pathway to the manifestations of metabolic syndrome*. Obesity research, 2004. **12**(2): p. 180-6.
108. Talukdar, S., J.M. Olefsky, and O. Osborn, *Targeting GPR120 and other fatty acid-sensing GPCRs ameliorates insulin resistance and inflammatory diseases*. Trends in pharmacological sciences, 2011. **32**(9): p. 543-50.
109. Makowski, L., et al., *The fatty acid-binding protein, aP2, coordinates macrophage cholesterol trafficking and inflammatory activity. Macrophage expression of aP2 impacts peroxisome proliferator-activated receptor gamma and IkappaB kinase activities*. The Journal of biological chemistry, 2005. **280**(13): p. 12888-95.

110. Furuhashi, M. and G.S. Hotamisligil, *Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets*. Nature reviews. Drug discovery, 2008. **7**(6): p. 489-503.
111. Schaeffler, A., et al., *Fatty acid-induced induction of Toll-like receptor-4/nuclear factor-kappaB pathway in adipocytes links nutritional signalling with innate immunity*. Immunology, 2009. **126**(2): p. 233-45.
112. Hertzfel, A.V. and D.A. Bernlohr, *The mammalian fatty acid-binding protein multigene family: molecular and genetic insights into function*. Trends in endocrinology and metabolism: TEM, 2000. **11**(5): p. 175-80.
113. Schroeder, F., et al., *Role of fatty acid binding proteins and long chain fatty acids in modulating nuclear receptors and gene transcription*. Lipids, 2008. **43**(1): p. 1-17.
114. Frolov, A. and F. Schroeder, *Acyl coenzyme A binding protein. Conformational sensitivity to long chain fatty acyl-CoA*. The Journal of biological chemistry, 1998. **273**(18): p. 11049-55.
115. Hertzfel, A.V., A. Bennaars-Eiden, and D.A. Bernlohr, *Increased lipolysis in transgenic animals overexpressing the epithelial fatty acid binding protein in adipose cells*. Journal of lipid research, 2002. **43**(12): p. 2105-11.
116. Spiegelman, B.M., M. Frank, and H. Green, *Molecular cloning of mRNA from 3T3 adipocytes. Regulation of mRNA content for glycerophosphate dehydrogenase and other differentiation-dependent proteins during adipocyte development*. The Journal of biological chemistry, 1983. **258**(16): p. 10083-9.
117. Hunt, C.R., et al., *Adipocyte P2 gene: developmental expression and homology of 5'-flanking sequences among fat cell-specific genes*. Proceedings of the National Academy of Sciences of the United States of America, 1986. **83**(11): p. 3786-90.
118. Haunerland, N.H. and F. Spener, *Fatty acid-binding proteins--insights from genetic manipulations*. Progress in lipid research, 2004. **43**(4): p. 328-49.
119. Makowski, L. and G.S. Hotamisligil, *The role of fatty acid binding proteins in metabolic syndrome and atherosclerosis*. Current opinion in lipidology, 2005. **16**(5): p. 543-8.
120. Fu, Y., N. Luo, and M.F. Lopes-Virella, *Oxidized LDL induces the expression of ALBP/aP2 mRNA and protein in human THP-1 macrophages*. Journal of lipid research, 2000. **41**(12): p. 2017-23.
121. Fu, Y., et al., *The adipocyte lipid binding protein (ALBP/aP2) gene facilitates foam cell formation in human THP-1 macrophages*. Atherosclerosis, 2002. **165**(2): p. 259-69.
122. Llaverias, G., et al., *Atorvastatin reduces CD68, FABP4, and HBP expression in oxLDL-treated human macrophages*. Biochemical and biophysical research communications, 2004. **318**(1): p. 265-74.
123. Coleman, S.L., Y.K. Park, and J.Y. Lee, *Unsaturated fatty acids repress the expression of adipocyte fatty acid binding protein via the modulation of histone deacetylation in RAW 264.7 macrophages*. European journal of nutrition, 2011. **50**(5): p. 323-30.

124. Makowski, L. and G.S. Hotamisligil, *Fatty acid binding proteins--the evolutionary crossroads of inflammatory and metabolic responses*. The Journal of nutrition, 2004. **134**(9): p. 2464S-2468S.
125. Chawla, A., et al., *A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis*. Molecular cell, 2001. **7**(1): p. 161-71.
126. Pascual, G., et al., *A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma*. Nature, 2005. **437**(7059): p. 759-63.
127. Hui, X., et al., *Adipocyte fatty acid-binding protein modulates inflammatory responses in macrophages through a positive feedback loop involving c-Jun NH2-terminal kinases and activator protein-1*. The Journal of biological chemistry, 2010. **285**(14): p. 10273-80.
128. Reynolds, J.M., et al., *Deficiency of fatty acid-binding proteins in mice confers protection from development of experimental autoimmune encephalomyelitis*. Journal of immunology, 2007. **179**(1): p. 313-21.
129. Hostetler, H.A., et al., *L-FABP directly interacts with PPARalpha in cultured primary hepatocytes*. Journal of lipid research, 2009. **50**(8): p. 1663-75.
130. Wolfrum, C., et al., *Fatty acids and hypolipidemic drugs regulate peroxisome proliferator-activated receptors alpha - and gamma-mediated gene expression via liver fatty acid binding protein: a signaling path to the nucleus*. Proceedings of the National Academy of Sciences of the United States of America, 2001. **98**(5): p. 2323-8.
131. Helledie, T., et al., *Lipid-binding proteins modulate ligand-dependent trans-activation by peroxisome proliferator-activated receptors and localize to the nucleus as well as the cytoplasm*. Journal of lipid research, 2000. **41**(11): p. 1740-51.
132. Feinstein, D.L., et al., *Peroxisome proliferator-activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis*. Annals of neurology, 2002. **51**(6): p. 694-702.
133. Tinahones, F.J., et al., *The retinoic acid receptor-related orphan nuclear receptor gamma1 (RORgamma1): a novel player determinant of insulin sensitivity in morbid obesity*. Obesity, 2012. **20**(3): p. 488-97.
134. Na, S.Y., et al., *Retinoids inhibit interleukin-12 production in macrophages through physical associations of retinoid X receptor and NFkappaB*. The Journal of biological chemistry, 1999. **274**(12): p. 7674-80.
135. Xu, J., et al., *Agonists for the peroxisome proliferator-activated receptor-alpha and the retinoid X receptor inhibit inflammatory responses of microglia*. Journal of neuroscience research, 2005. **81**(3): p. 403-11.
136. Uysal, K.T., et al., *Improved glucose and lipid metabolism in genetically obese mice lacking aP2*. Endocrinology, 2000. **141**(9): p. 3388-96.
137. Hotamisligil, G.S., et al., *Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte fatty acid binding protein*. Science, 1996. **274**(5291): p. 1377-9.

138. Boord, J.B., et al., *Combined adipocyte-macrophage fatty acid-binding protein deficiency improves metabolism, atherosclerosis, and survival in apolipoprotein E-deficient mice*. *Circulation*, 2004. **110**(11): p. 1492-8.
139. Lawrie, L.C., et al., *Liver fatty acid binding protein expression in colorectal neoplasia*. *British journal of cancer*, 2004. **90**(10): p. 1955-60.
140. Mazzanti, R., et al., *Differential expression proteomics of human colon cancer*. *American journal of physiology. Gastrointestinal and liver physiology*, 2006. **290**(6): p. G1329-38.
141. Boiteux, G., et al., *A-FABP, a candidate progression marker of human transitional cell carcinoma of the bladder, is differentially regulated by PPAR in urothelial cancer cells*. *International journal of cancer. Journal international du cancer*, 2009. **124**(8): p. 1820-8.
142. Mita, R., et al., *B-FABP-expressing radial glial cells: the malignant glioma cell of origin?* *Neoplasia*, 2007. **9**(9): p. 734-44.
143. Das, R., et al., *Expression pattern of fatty acid-binding proteins in human normal and cancer prostate cells and tissues*. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 2001. **7**(6): p. 1706-15.
144. Nieman, K.M., et al., *Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth*. *Nature medicine*, 2011. **17**(11): p. 1498-503.
145. Hancke, K., et al., *Adipocyte fatty acid-binding protein as a novel prognostic factor in obese breast cancer patients*. *Breast cancer research and treatment*, 2010. **119**(2): p. 367-7.
146. Ordovas, J.M., *Identification of a functional polymorphism at the adipose fatty acid binding protein gene (FABP4) and demonstration of its association with cardiovascular disease: a path to follow*. *Nutrition reviews*, 2007. **65**(3): p. 130-4.
147. Maeda, K., et al., *Adipocyte/macrophage fatty acid binding proteins control integrated metabolic responses in obesity and diabetes*. *Cell metabolism*, 2005. **1**(2): p. 107-19.
148. Hertzog, A.V., et al., *Identification and characterization of a small molecule inhibitor of Fatty Acid binding proteins*. *Journal of medicinal chemistry*, 2009. **52**(19): p. 6024-31.
149. Biswas, S.K. and C.E. Lewis, *NF-kappaB as a central regulator of macrophage function in tumors*. *Journal of leukocyte biology*, 2010. **88**(5): p. 877-84.
150. Sacconi, A., et al., *p50 nuclear factor-kappaB overexpression in tumor-associated macrophages inhibits M1 inflammatory responses and antitumor resistance*. *Cancer research*, 2006. **66**(23): p. 11432-40.
151. Flegal, K.M., et al., *Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010*. *JAMA : the journal of the American Medical Association*, 2012. **307**(5): p. 491-7.
152. Sica, A., et al., *Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy*. *European journal of cancer*, 2006. **42**(6): p. 717-27.

153. Mantovani, A., et al., *Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes*. Trends in immunology, 2002. **23**(11): p. 549-55.
154. Vicari, A.P. and G. Trinchieri, *Interleukin-10 in viral diseases and cancer: exiting the labyrinth?* Immunological reviews, 2004. **202**: p. 223-36.
155. Trinchieri, G., *Interleukin-10 production by effector T cells: Th1 cells show self control*. The Journal of experimental medicine, 2007. **204**(2): p. 239-43.
156. Salcedo, R., et al., *MyD88-mediated signaling prevents development of adenocarcinomas of the colon: role of interleukin 18*. The Journal of experimental medicine, 2010. **207**(8): p. 1625-36.
157. Mumm, J.B., et al., *IL-10 elicits IFN γ -dependent tumor immune surveillance*. Cancer cell, 2011. **20**(6): p. 781-96.
158. Reka, A.K., et al., *Molecular cross-regulation between PPAR- γ and other signaling pathways: implications for lung cancer therapy*. Lung cancer, 2011. **72**(2): p. 154-9.
159. Jarrar, M.H. and A. Baranova, *PPAR γ activation by thiazolidinediones (TZDs) may modulate breast carcinoma outcome: the importance of interplay with TGF β signalling*. Journal of cellular and molecular medicine, 2007. **11**(1): p. 71-87.
160. Wang, L.H., et al., *Inhibition of adhesive interaction between multiple myeloma and bone marrow stromal cells by PPAR γ cross talk with NF- κ B and C/EBP*. Blood, 2007. **110**(13): p. 4373-84.
161. Hetzel, M., et al., *Inhibition of MMP-9 expression by PPAR γ activators in human bronchial epithelial cells*. Thorax, 2003. **58**(9): p. 778-83.
162. Peeters, L.L., et al., *PPAR γ represses VEGF expression in human endometrial cells: implications for uterine angiogenesis*. Angiogenesis, 2005. **8**(4): p. 373-9.
163. Yang, B., et al., *PPAR γ agonists diminish serum VEGF elevation in diet-induced insulin resistant SD rats and ZDF rats*. Biochemical and biophysical research communications, 2005. **334**(1): p. 176-82.
164. King, E.B., et al., *Analytic studies of foam cells from breast cancer precursors*. Cytometry, 1984. **5**(2): p. 124-30.
165. Yang, Z., et al., *Macrophage α 1 AMP-activated protein kinase (α 1AMPK) antagonizes fatty acid-induced inflammation through SIRT1*. The Journal of biological chemistry, 2010. **285**(25): p. 19051-9.
166. Schultze, S.M., et al., *PI3K/AKT, MAPK and AMPK signalling: protein kinases in glucose homeostasis*. Expert reviews in molecular medicine, 2012. **14**: p. e1.
167. Shackelford, D.B. and R.J. Shaw, *The LKB1-AMPK pathway: metabolism and growth control in tumour suppression*. Nature reviews. Cancer, 2009. **9**(8): p. 563-75.
168. Gallagher, E.J. and D. LeRoith, *Diabetes, cancer, and metformin: connections of metabolism and cell proliferation*. Annals of the New York Academy of Sciences, 2011. **1243**: p. 54-68.

169. Morizane, Y., et al., *AMP-activated Protein Kinase Suppresses Matrix Metalloproteinase-9 Expression in Mouse Embryonic Fibroblasts*. The Journal of biological chemistry, 2011. **286**(18): p. 16030-8.
170. Dirat, B., et al., *Cancer-associated adipocytes exhibit an activated phenotype and contribute to breast cancer invasion*. Cancer research, 2011. **71**(7): p. 2455-65.
171. Onuma, M., et al., *Prostate cancer cell-adipocyte interaction: leptin mediates androgen-independent prostate cancer cell proliferation through c-Jun NH2-terminal kinase*. The Journal of biological chemistry, 2003. **278**(43): p. 42660-7.
172. Carter, J.C. and F.C. Church, *Mature breast adipocytes promote breast cancer cell motility*. Experimental and molecular pathology, 2012.
173. Elmasri, H., et al., *Fatty acid binding protein 4 is a target of VEGF and a regulator of cell proliferation in endothelial cells*. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2009. **23**(11): p. 3865-73.
174. Lee, M.Y., et al., *Chronic administration of BMS309403 improves endothelial function in apolipoprotein E-deficient mice and in cultured human endothelial cells*. British journal of pharmacology, 2011. **162**(7): p. 1564-76.
175. Kollarova, H., et al., *Is obesity a preventive factor for lung cancer?* Neoplasma, 2008. **55**(1): p. 71-3.

CURRICULUM VITAE

NAME: Ashley Simone Triplett

CONTACT: University of Louisville, Dept. of Microbiology and Immunology
319 Abraham Flexner Way, Room 311 Louisville, KY 40202
Cell: (313) 258-5744, Work: (502) 852-6979
astrip01@louisville.edu

EDUCATION

2012 Ph.D., Immunology
University of Louisville, Louisville KY

2009 M.S., Immunology
University of Louisville, Louisville KY

2007 B.S., Biology Major, Chemistry Minor
Tennessee State University, Nashville TN

RESEARCH AND PROFESSIONAL EXPERIENCE

2012-Present Postdoctoral Fellow, Laboratory of Molecular Immunoregulation,
Tumor Immunity and Tolerance Section, Center for Cancer
Research, National Cancer Institute, Frederick, MD.

2007 – 2012 Graduate Research Student, Department of Microbiology and
Immunology, University of Louisville, Louisville KY

Fall 2006 Undergraduate Research Student, Microbiology
Tennessee State University, Nashville TN

Summer 2006 Undergraduate Research Student, Microbiology
University of Minnesota, Minneapolis MN

2004 – 2006 Undergraduate Research Student, Pharmacology
Tennessee State University, Nashville TN

AWARDS

2012	Cancer Research Training Award, NCI
2011	FASEB/MARC Program Poster/Oral Presentation Travel Award
2011	University of Louisville, School of Interdisciplinary and Graduate Studies Minority Doctoral Dissertation Award
2010	FASEB/MARC Program Poster/Oral Presentation Travel Award
2010	American Association of Immunologists Trainee Abstract Award
2009	American Association of Immunologists Minority Scientist Travel Award
2008	Graduate Student Council Travel Award, University of Louisville
2007	University of Louisville, Integrated Programs in Biomedical Sciences Fellowship
2006	FASEB/MARC Undergraduate Student Training in Academic Research Fellowship
2005	Sigma Xi Scientific Research Society Award

MEMBERSHIPS

Society for Leukocyte Biology

American Association for Cancer Research

American Association of Immunologists

Microbiology and Immunology Student Organization

Black Biomedical Graduate Student Organization

Beta Kappa Chi Scientific Honor Society

POSTER PRESENTATIONS

1. **Triplett, A.**, Gralnick, J. *Identification of Antibiotic Resistant Genes in Escherichia coli and Citrobacter*. Tennessee Lois-Stokes Alliance for Minority Programs Research Conference, 2006.
2. **Triplett, A.**, Gralnick, J. *Identification of Antibiotic Resistant Genes in Escherichia coli and Citrobacter*. Life Sciences Summer Undergraduate Research Symposium, University of Minnesota, 2006.

3. Azeem, A., **Triplett, A.**, Alard, A., Kosiwicz, M. *IL-6 may interfere with the development of functional adaptive Tregs in NOD mice*. American Association of Immunologists Annual Meeting, 2009.
4. **Triplett, A.**, Singh, R., Sharma, P., Lillard, J., Singh, S. *CXCR6-Mediated Cellular and Molecular Events Involved in Breast Cancer Cell Migration and Invasion*. American Association of Immunologists Annual Meeting, 2010.
5. **Triplett, A.**, Li, B., Vanchinathan, M., Hansen, R., Suttles, J. *A-FABP Deficiency in Mice Provides Protection from Tumor Growth and Metastasis*. Society for Leukocyte Biology Annual Meeting, 2010.

ORAL PRESENTATIONS

1. **Triplett, A.**, Li, B., Suttles, J. *Expression of Adipocyte/Macrophage-Fatty Acid Binding Protein Promotes Tumor Growth and Metastasis*. Society for Leukocyte Biology Annual Meeting, 2011.

PUBLICATIONS

Published Abstracts

Azeem, A., **Triplett, A.S.**, Parnell, S, Zhao, Y., Alard, P., Kosiewicz, M. 2009. *IL-6 may interfere with the development of functional adaptive Tregs in NOD mice*. J. Immunol. 182: 48.19.

Triplett, A., Sharma, P., Singh, R., Lillard, J., Singh, S. 2010. *CXCR6-Mediated Cellular and Molecular Events Involved in Breast Cancer Cell Migration and Invasion*. J. Immunol. 184: 133.6.

Triplett, A.S., Li, B., and Suttles, J. 2011. *Expression of Adipocyte/Macrophage-Fatty Acid Binding Protein Promotes Tumor Growth and Metastasis*. J. Leuk. Biol. S5 Abst.16.

Manuscripts in Preparation

Triplett, A.S., Li, B., Stout, R.D., Bernlohr, D.A., Suttles, J. 2012. *Expression of Adipocyte/Macrophage-Fatty Acid Binding Protein Promotes Tumor Growth and Metastasis*.